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ABSTRACT 
Phenotypic Heterogeneity of Breast Tumors 
Alexandra P. Vamvakidou 
Aydin Tozeren, Ph.D. 
 
 
 
 
Breast tumors are typically heterogeneous and contain diverse subpopulations of tumor 
cells with differing phenotypic properties. In order to identify potential biomarkers of 
relapse in breast cancer, we have analyzed relapse related microarray data from five 
different laboratories and identified a list of significantly altered genes for each dataset. 
KEGG pathways for MAPK signaling, focal adhesion and cytokine-mediated signaling 
have been enriched for relapse in breast cancer in four out of the five microarray 
databases. We found that a set of genes coding for extracellular proteins are consistently 
upregulated in breast cancer patients with relapse in a multitude of microarray databases. 
A significant subset of these genes code for proteins found in the serum and as such could 
be potential candidates for relapse biomarkers. In addition, our work presents an in vitro 
coculture-based three-dimensional heterogeneous breast tumor model that can be used in 
drug resistance and drug delivery investigations. Breast cancer cell lines of different 
phenotypes (MDAMB231, MCF7 and ZR751) were cocultured in a rotating wall vessel 
(RWV) bioreactor to form a large number of heterogeneous tumoroids in a single cell 
culture experiment. In vitro tumoroids developed in this study recapture important 
features of the temporal-spatial organization of solid tumors, including the presence of 
necrotic areas at the center and higher levels of cell division at the tumor periphery. E-cad 
positive MCF7 cells form larger tumoroids than E-cad negative MDAMB231 cells.  In 
addition, we present an automated image analysis protocol for detailed morphological 
 xi
protein marker profiling of tumoroid cross section images. Histologic cross sections of 
breast tumoroids developed in coculture suspensions of breast cancer cell lines, stained 
for E-cadherin and progesterone receptor, were digitized and pixels in these images were 
classified into five categories using k-means clustering. Proposed image analysis methods 
offer standardized high throughput profiling of molecular anatomy of tumoroids based on 
both membrane and nuclei markers that is suitable to rapid large scale investigations of 
anti-cancer compounds for drug development.  
 1 
CHAPTER 1: Introduction 
1.1 Motivation 
Our study’s focus is to provide new understanding of the cellular interactions that occur 
in a heterogeneous tumor environment, as well as the dynamics that these interactions 
may have in tumor growth, and ultimately therapy. This will in turn enhance the 
understanding of phenotypic behavior of breast cancer cells for the following reasons: a) 
examination of the levels of aggressiveness of tumors and their growth is important when 
trying to develop novel methods of cancer therapy and new models of tumor 
development b) the survival of patients is dependent on attempts to improve the ability to 
target and isolate the rapidly proliferating cancer cells c) the current studies and practices 
lead to short term solutions d) the importance of battling a disease such as cancer and 
specifically breast cancer, which is one of the highest occurring types in women 
(American Cancer Society, 2004). 
 
1.2 Current Status and Problems 
The breast is a gland that produces and secretes milk (Figure 1). Milk is produced in the 
lobules and drained through the ducts to the nipple. Breast cancer is the result of 
uncontrolled growth of breast cells, and is the most commonly occurring cancer among 
women (American Cancer Society, 2004). It can be initiated in the lobules or in the ducts 
and could either be noninvasive, when confined to the site of origin, or invasive, where 
cancer cells spread beyond the basement membrane, which covers the underlying 
connective tissue in the breast, and are carried to other areas of the body through the 
blood vessels and lymphatic channels (Zavagno et al., 2005). 
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Figure 1 Breast anatomy (King et al., 2005). 
 
1.2.1 Risk factors 
Breast tumorigenesis is associated with several risk factors. Age is a major risk factor 
where it has been found that more than 80% of breast cancer cases occur in women over 
the age of 50 (Cancer Research UK, 2004). Other factors include ethnicity, heredity and 
family history, sensitivity to estrogens, abnormalities or breast conditions, physical 
characteristics such as obesity, and environmental factors (McTiernan et al., 1998). 
1.2.1 Detection 
Early breast cancer detection and diagnosis is crucial. Treatment in the earlier stages is 
more likely to be effective, when tumor growth, proliferation and invasion of surrounding 
tissue are limited. Mammogram screening is followed by surgical biopsy, in which the 
patients have to undergo an operation to remove tissue samples, and an examination by a 
pathologist to determine if the detected tumor is benign or malignant (Caines et al., 
2005). 
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1.3 Gene Expression Profiling 
In addition to using biopsy procedures, a major focus of breast cancer research has been 
to identify molecular changes in breast tissue. Significant research has been focused on 
locating gene and protein markers associated with breast cancer. Gene expression 
profiling and proteomics provide novel insights into cancer-related traits. Several 
investigators have performed comparisons of genetic expression profiles of cancerous 
versus normal tissues. A normal cell goes through several alterations, by which 
hyperplasia, premalignancy and in situ carcinoma occurs.  Genetic analysis has shown 
that cancer derived cells have chromosomal changes, in lower frequencies than in tumors 
(Peehl et al., 2005), therefore making the use of three-dimensional multicellular 
tumoroids appropriate when studying gene expression profiles of tumor samples. 
 
1.4 Prognostic factors 
Pathologists consider furthermore several prognostic factors, characteristic of breast 
tumors, which are important in determining the possibility of reoccurrence in later stages. 
Before deciding on the best course of treatment, tumor type and size are considered. 
Tumor size has been recognized as the most effective prognostic factor of the outcome of 
patients with invasive breast carcinoma. There have been several studies that examined 
the possible correlation between tumor size and patient survival rates (Michaelson et al., 
2002). 
 
In a study, researchers aimed to predict the survival rate of patients with breast carcinoma 
using tumor size, and results of their mathematical model showed that the reduction of 
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tumor size may be an important factor in the reduction of deaths, related to the decline of 
the number of cells in the tumor. Cells in the periphery of the tumor have increased 
chances of detaching from the tumor as the tumor grows, while the center of the tumor 
begins to accumulate necrotic material (Michaelson et al., 2002), an effect of hypoxia. 
 
Another important prognostic factor is lymph node involvement, which is determined by 
a procedure called an auxiliary lymphadenectomy (Figure 2), where a physician removes 
the lymph nodes in the armpit on the side of the affected breast to verify whether or not 
cancer cells are present in the lymph nodes (Marchal et al., 2005). 
 
 
Figure 2 The number of lymph nodes containing cancer cells determines the staging of 
breast cancer. Breast cancer spreads first to the auxiliary lymph nodes, known as regional 
spread. Metastasis to other areas of the body can occur at later stages (Imaginis 
Corporation, 2005). 
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Hormone receptor status is used to distinguish between hormone dependent and hormone 
independent tumors. Hormone dependent tumors are sensitive to the female growth 
hormones estrogen and progesterone. These types of tumors are characterized as estrogen 
receptor positive (ER+), or progesterone receptor (PR+) or both. In approximately two 
thirds
 
of all breast tumors, the estrogen receptor (ER) is present
 
and functionally active. 
Hormone independent tumor cells do not contain hormone receptors and therefore are 
characterized as estrogen negative (ER-), and progesterone negative (PR-). Hormone 
independent tumors are highly aggressive compared to hormone sensitive tumors. The 
presence of the ER in breast
 
carcinoma cells and their responsiveness to estrogens 
clinically
 
permits treatment with antiestrogens. Tamoxifen is an antiestrogen drug that 
blocks the binding of estrogens to estrogen receptor of human breast cancer cells (Jordan, 
1997). In an alternative strategy, formestane, exemestane and anastrozole (Brodie, 2002) 
are inhibitors of aromatase, which is important in estrogen synthesis. As a consequence, 
the antiestrogen-receptor complex
 
may bind DNA but can no longer modulate the 
expression of its
 
target genes. This inhibition of the estrogen response
 
pathway may block 
cellular proliferation and arrest
 
tumor growth. 
 
Other prognostic factors include histological grade (Figure 3) which refers to the degree 
that tumor cells resemble normal cells and the extent of differentiation, and proliferation 
capacity of a tumor, as referred to the rate at which cancer cells divide, a factor which is 
related to the aggressiveness levels of tumor cells (Tozeren et al., 2005). 
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Figure 3 Five major observable tissue structures characteristic of a given histological 
breast cancer slide NM1: the nuclei of inflammatory cells and lymphocytes, NM2: nuclei: 
nuclei of cells of epithelial origin having nearly uniform chromatin distribution. These 
nuclei are significantly larger than the nuclei of lymphocytes. NM3 nuclei: nuclei of 
cancer cells with non–uniform chromatin distribution, usually large and weak, ECM 
(extra-cellular matrix): collagen based support structure, AT (adipose tissue): areas 
representing water, carbohydrate, lipid or gas (Petushi et al., 2004). 
 
1.5 Treatment and Therapy 
Depending on the outcome of prognosis, a method of treatment is determined. Primary 
therapy for breast cancer involves lumpectomy or mastectomy and radiation therapy, 
where both the tumor and a small amount of the surrounding tissue or the whole breast, 
lymph nodes and lining over the chest muscles are removed. Adjuvant therapy has as a 
purpose to kill any cancer cells that may have spread, and includes a combination of 
chemotherapy and hormone therapy in cases of hormone dependent tumors (Untch et al., 
2000). 
 
Chemotherapy attacks proliferating cells, and prevents the original cancer from returning. 
Side effects include loss of energy, nausea, and increased susceptibility to infections. 
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Hormone therapy deprives cancer cells of the female growth hormones by blocking the 
hormone receptor, this way inhibiting growth. Methods such as chemotherapy, radiation 
therapy and immunotherapy in principle, attack breast cancer cells. However, if that fails, 
and the cancer cells survive, they have an increased resistance to therapy, and 
phenotypically they become more aggressive, with a higher inclination to metastasize.  
 
Other procedures include oophorectomy, which is a surgery in which the ovaries are 
removed, eliminating the body's main source of estrogen and progesterone in 
premenopausal women (Metcalfe et al., 2005). 
 
1.6 Rotating Wall Vessel Bioreactors 
Tumor formations are created in a cell culture environment called rotating wall vessel 
(RWV) bioreactor, which facilitates the generation of functional three-dimensional tissue 
constructs. The vessel rotates as a whole body around a horizontal axis, at a rotational 
speed, which sustains the suspended cells in a state of free fall. It is a culture environment 
with low shear forces, high mass transfer and microgravity conditions, which enables 
three-dimensional cell growth (Lelkes et al., 2002).  
 
In our study, we are using high aspect ratio vessels (HARVs) (Figure 4), which are 
unique when cells require a higher oxygen tension. HARVs are discoids that contain a 
gas exchange membrane (Freed et al., 1997). 
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Figure 4 The HARV bioreactor. The RWV was designed to mimic microgravity, the 
vessel spins at a fast enough speed overcoming friction, and allowing the cells that are in 
suspension, to aggregate thereby forming tissue-like constructs. 
 
1.7 Tumor Heterogeneity 
Tumor heterogeneity is responsible for the resistance to cytotoxic effects of cancer 
therapies (Desoize et al., 1998). Three-dimensional expansion, cell-cell interactions, and 
environmental tumor growth conditions are a few aspects of tumor heterogeneity (Burns 
et al., 2005). In the past, it was determined that in vitro formed tumor structures possess 
the gradient distribution of viability, differentiation, and gene expression (Mueller-
Klieser, 1997; O’Connor, 1999), therefore, making these multicellular aggregates a 
valuable model in drug and cancer therapy research.  
 
In our study, we are comparing the effects of hypoxia, and aggressiveness in relation to 
the rates of migration, proliferation, metabolic activity, and to the spatial distribution of 
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breast cancer cells in three-dimensional tumoroids. It is of interest to examine to what 
extent the current therapies are able to treat the tumoroids that mimic the spatial 
organization and composition of tumors. Therefore, multicellular aggregates of breast 
cancer cells are a valuable model in drug and cancer therapy research. 
 
1.8 Cancer Cell Lines as Model Systems 
Cell lines have long be used as model systems in cancer research.  The development and 
application of cell and tumor models could be useful in accurately portraying human 
tumorigenesis. Human cancer cell lines provide the molecular and cellular foundation of 
cancer development and tumor growth. In our study we emphasize the ability of breast 
cancer cells to model the processes involved in breast carcinogenesis.  
 
The events during cancer progression and cell differentiation have been under study. 
Several models have been proposed that take into account population dynamics on 
patterns produced by clusters of cells (Lim et al., 1990) as well as on the growth of 
anchorage-dependent cells (Ruaan et al., 1993) which studied cell movement during the 
first stages after division (Zygourakis et al., 1996). 
 
Human cell lines are representative model systems for studies of cancer. In immune 
deficient mice, it was observed that invasive cancer cells, formed tumors (Thompson et 
al., 1992; Nakayama et al., 1998). Preliminary experiments are conducted on three human 
breast cancer cell lines, namely, the hormone-dependent breast cancer cell lines, MCF7, 
ZR751 human ductal carcinoma (HDC), and the hormone-independent breast cancer cell 
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line, MDAMB231 (Figure 5). These cell lines have been widely used in breast cancer 
research.  
 
 
Figure 5 Three breast cancer cell lines: a) MCF7 hormone-dependent breast cancer cell 
line. Epithelial-like cells that grow as monolayers. ER+ and low metastatic. b) ZR751 
(HDC) human ductal carcinoma c) MDAMB231 hormone-independent breast cancer cell 
line which is ER- and highly metastatic. 
 
1.8.1 Low Aggressive Breast Cancer Cell Line MCF7 
MCF7 cells are epithelial-like cells. These cells grow as monolayers and were described 
to be positive for cytoplasmic estrogen receptors (Soule et al., 1973). Tumor necrosis 
factor alpha inhibits growth of MCF7 cells (Sugarman et al., 1985). MCF7 cells secrete 
insulin-like growth factor binding proteins (IGFBP) that can be modulated by estrogens 
and antiestrogens (Pratt et al., 1993). MCF7 cells are low metastatic breast cancer cells. 
Phenotypically MCF7 prior to chemotherapy appear to be hormone dependent, non-
metastatic and anti-estrogen sensitive. After chemotherapy, their chemo-resistance 
increases, and they become hormone independent, invasive, metastatic and anti-estrogen 
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resistant (Simstein et al., 2003). MCF7 appear to reflect the heterogeneity of tumor cells 
in vivo. 
 
1.8.2 Low Aggressive Breast Cancer Cell Line ZR751 
Mammary tumor cell line ZR751 has been established from malignant effusions of a 
woman with breast cancer. Differentiated properties expressed include epithelial 
morphology resembling that of the parental tumors; presence of receptors for estrogen 
and other steroid hormones, and growth responsiveness to estrogen and progesterone 
(Engel et al., 1978). 
 
1.8.3 Highly Aggressive Breast Cancer Cell Line MDAMB231 
MDAMB231 are epithelial-like cells and estrogen receptor negative (Cailleau et al., 
1974). MDAMB231 cells express high levels of transforming growth factor alpha and 
epidermal growth factor receptor mRNAs (Bates et al., 1990). This invasive, highly 
aggressive breast cancer cell line has been used in several studies including in formations 
of xenograft tumors in immune deficient mice which allowed the comparison of cells 
grown in vitro and in vivo. Results from this study showed that the culture environment 
produces distinct molecular and cellular properties, enhancing tumorigenesis (Jessani et 
al., 2004; Speers et al., 2004). 
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1.9 In Vitro Formed Tumoroids 
The limitations of two-dimensional cell culture systems are dependent on the lack of 
tissue-like specific functions and extensive cell-cell contacts. Our research examines 
tumor growth under various multicellular culture conditions. Experimental data of 
carcinogenesis and tumor growth of three-dimensional breast cancer tumoroids would 
further enable us to accurately establish a model for tumor progression. In a recent 
stochastic model (Figure 6), it was proposed that there exist three types of aggressiveness 
levels, A1, which is characteristic of low aggressive, low metastatic and slow 
proliferating cells, A2, typical of medium aggressiveness, and increased levels of 
migration and proliferation, and lastly, A3 representative of the highly aggressive cell 
lines, which have are resistant to drugs and have the ability to stimulate the growth of 
micro-vessels (Tozeren et al., 2005). 
 
 
Figure 6 Tumor progression examples of experimental and predicted tumor shapes 
(Tozeren et al., 2005). 
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Three-dimensional cell aggregates have the advantage of having a well-defined 
geometry, which makes it possible to correlate structure to function. Tumoroids resemble 
cell shape and cellular environment, which can determine gene expression and biological 
behavior of cells. They also are very good models of initial, avascular growth stage 
malignancies, with micrometastases, and with intercappilary tumor microregions 
(Mueller-Klieser, 1987). 
 
Tumoroids are characterized by concentric arrangement of heterogeneous cell 
populations, with proliferative cells at the periphery, and a necrotic core, which is a result 
of limited oxygen diffusion (Mueller-Klieser, 1997). This model describes hypoxic 
events, the effects of lack of nutrients, accumulation of waste products and low pH levels 
which results to metabolic gradients prior to necrosis (Mueller-Klieser, 1997). 
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CHAPTER 2: Genes Associated with Focal Adhesion, MAPK signaling and 
Cytokine Receptor Interaction Pathways are Determinants of Relapse in Breast 
Cancer 
 
Summary 
This chapter focuses on the identification of breast cancer biomarkers for relapse. My 
collaborators in this chapter were Adam Ertel, Michael Gormley, Dr. Andrew Quong and 
Dr. Aydin Tozeren. The manuscript based on this chapter was recently submitted to BMC 
Breast Cancer Research (Vamvakidou et al., 2007 II). Identification of breast cancer 
biomarkers for relapse is important for developing individualized therapies covering a 
range of interventions from tumor excision, standard chemotherapy to vaccine therapy. 
Proteins used in cell communication and signaling are potential biomarkers for a number 
of disease states involving inflammation, and cancer. In order to identify potential 
biomarkers of relapse in breast cancer, we have analyzed relapse related microarray data 
from five different laboratories and additional data on breast cancer cell lines with poorly 
invasive and highly invasive cell phenotypes. We have identified a list of significantly 
altered genes for each dataset, and using a hypergeometric test, we computed the KEGG 
pathways that are significantly enriched in breast cancer relapse cases. KEGG pathways 
for MAPK signaling, focal adhesion and cytokine-mediated signaling have been enriched 
for relapse in breast cancer in four out of the five microarray databases. Genes coding for 
extracellular proteins along these pathways were consistently upregulated in breast cancer 
patients with relapse. Genes along the same signaling and communication pathways were 
upregulated in highly invasive breast cancer cell lines compared to poorly invasive 
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cultured cells. A 16 gene biomarker set taken from genes in the enriched pathways 
predicted relapse with nearly 80% accuracy in an independent microarray dataset. A 
subset of genes coding for extracellular proteins along signaling and communication 
pathways are consistently upregulated in breast cancer patients with relapse in a 
multitude of microarray databases. Majority of these genes codes for proteins found in 
the serum. Present study points out the potential of serum protein subsets in predicting 
relapse in breast cancer.  
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2.1 Introduction 
Breast cancer is a clinically, genetically and morphologically heterogeneous disease. 
Early detection and diagnosis is crucial to survival outcome. Pathologists consider several 
prognostic factors characteristic for breast tumors, such as hormone receptor status, 
lymph node involvement and histological tumor grade prior to prescribing a course of 
treatment (Winer et al., 2001). Recent studies on breast cancer relapse focused on 
augmenting standard histology data with molecular profiling of breast tumor in order to 
predict response to therapy. Global gene expression allows for simultaneous monitoring 
of thousands of genes per sample, thus providing molecular and genetic snap shots of 
biological systems.  
 
Gene expression profiling studies have been performed to investigate metastasis, tumor 
classification and to identify genetic signatures that predict prognosis and disease 
outcome (Perou et al., 2000; Hedenfalk et al., 2001; Gruvberger et al., 2001; van’t Veer 
et al., 2002; Hedenfalk et al., 2003; Pawitan et al., 2005; Wang et al., 2005; Minn et al., 
2005). Gene expression profiling assays such as Oncotype DX (21-gene panel; Genomic 
Health); MammaPrint (70-gene panel; Agendia); and 76-gene panel (Veridex) were 
developed to predict the likelihood of breast cancer recurrence. However, the biomarker 
gene subsets from these groups share only a small number of common elements. In fact, 
microarray data obtained in different laboratories for breast cancer and its subtypes lead 
to different lists of statistically significant genes in comparisons between patient 
subpopulations. Wide variation in significant gene lists may stem from the statistical 
methods used in the identification of gene subsets as biomarkers. It is also highly feasible 
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that the molecular heterogeneity of breast tumors is the leading cause of variation in the 
list of significant genes between patient subset comparisons. For this reason, considerable 
research has focused on understanding tumor heterogeneity and its underlying effects on 
breast cancer development and behavior (Perou et al., 2000; Sorlie et al., 2001, 2003; 
Sotiriou et al., 2006).  Results from these studies suggest the presence of common 
molecular motifs for breast cancer metastasis despite extensive tumor heterogeneity.    
 
A multitude of breast tumor microarray datasets with extensive links to clinical data have 
become publicly accessible in recent years (Sorlie et al., 2003; Pawitan et al., 2005; 
Wang et al., 2005; Schuetz et al., 2006; Sotirou et al., 2006). These datasets comprise a 
rich source for the identification of genomic signatures associated with relapse in breast 
cancer. Two distinct approaches can be taken to extract, compare and integrate 
information from the multiple microarray breast cancer databases for identifying 
molecular relapse signatures in breast cancer. One option would be to combine multiple 
datasets and normalize them with the use of statistical considerations such as those 
developed by Rhodes et al. (2002), Choi et al. (2003), Rhodes et al. (2004), Shen et al., 
(2004), and Gentleman et al. (2005). These methods aim at generating gene subsets, 
cellular pathways and transcription factor networks from the processing of the combined 
data. The alternative approach adopted in the present study is to analyze each of the 
datasets independently using standard statistical approaches and then look for common 
motifs. This latter approach is simpler in concept in the sense that it avoids additional 
processing and statistical analysis required for combining databases into a meta-dataset 
(Ertel et al., 2006). Basically the approach yields a different list of significantly altered 
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genes between two conditions (relapse, non-relapse) for each dataset. These lists are then 
used in hyper geometric test to identify statistically enriched pathways in one group 
(relapse) compared to other (non-relapse). Once the enriched pathways are determined, 
the gene expression values of its element nodes are investigated for distinct patterns that 
differentiate the molecular profile of one clinical subtype of patients from another. In this 
article we utilized this approach and five different microarray datasets on breast cancer to 
identify relapse-associated alterations in the cellular signaling pathways.  
 
Three cellular pathways—MAPK, focal adhesion, and cytokine-cytokine receptor 
interaction—were mostly enriched in relapse compared to non-relapse comparisons. 
These communication pathways were also upregulated in sections of breast tumors 
containing invasive ductal carcinoma (IDC) compared with regions exhibiting ductal 
carcinoma in situ (DCIS). Similarly, MAPK, cytokine, and focal adhesion pathways were 
upregulated in highly invasive cancer cell lines compared to poorly invasive cell lines. 
Quantitative classification of patients into relapse and nonrelapse groups could be 
performed with nearly 80% accuracy with a 16 gene biomarker set selected from genes in 
the enriched pathways. 
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2.2 Methods 
2.2.1 Microarray Gene Expression Data 
Microarray profiles used in this study consisted of five publicly-accessible gene 
expression profile datasets derived from breast tumors, one from multiple tumor types 
used as control and two datasets involving three breast cancer cell lines (Table 1). All 
datasets were downloaded from NCBI’s Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) (Barrett et al., 2006; Edgar et al., 2002). Tumor 
datasets were limited to those that contained clinical data on relapse-status. Cell line 
datasets included both highly invasive (MDAMB231; BT474) and poorly invasive 
(MCF7) cultured cells.  
 
The datasets listed in Table 1 are as follows: (1) GSE1456 containing breast tumor 
samples used to identify women with a poor prognosis as candidates for adjuvant therapy 
(Pawitan et al., 2005); (2) GSE2990 breast tumor samples divided into two groups 
according to institution: Uppsala and John Radcliffe, used to determine association 
between histologic grade and gene expression profiles (Sotiriou et al. 2006); (3) 
GSE2034 breast tumor samples that were subclassified to improve individual risk 
assessment in patients with lymph-node-negative cancer (Wang et al., 2005); (4) cDNA 
data GSE4382-GPL180 to study previously characterized molecular subtypes (Sorlie et 
al., 2003); (5) GSE3893 containing ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC) samples to identify transition markers from DCIS to IDC (Schuetz et 
al., 2006), and (6) the GSE2109 tumor data from multiple tissue types (Table 1) that were 
clinically annotated for relapse since primary treatment. The cell line datasets involved 
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parental breast cancer cell line data for MCF7, BT474 (GSE3529) (Rae et al., 2005) and 
MDAMB231 (GSE2603) (Minn et al., 2005).  
 
Table 1 List of datasets used in the present study. 
Relapse 
Status  GEO ID Samples 
(-/+) 
Platform Reference 
GSE2034 
286 (Erasmus Medical 
Center) 
179/107 Affy U133A 
Wang et al. 
2005 
85 (Uppsala) 59/26 
GSE2990 
82 (John Radcliffe) 50/32 
Affy U133A 
Sotiriou et al. 
2006 
GSE1456 
128 (Karolinska 
Hospital) 
92/36 Affy U133A 
Pawitan et al. 
2005 
GSE4382-
GPL180 
64  (Stanford 
Microarray Database) 
50/14 cDNA 
Sorlie  et al., 
2003 
GSE3893 
DCIS and IDC 
(University Hospital 
Tuebingen) 
N/A Affy U133A 
Schuetz et al. 
2006 
B
re
a
st
 T
u
m
o
rs
 
N/A 51 (KF-SYSCC) 34/17 Affy U95Av2 
Huang et al., 
2003 
GSE2603 MCF7 and BT474 N/A Affy U133A Minn et al. 2005 
C
el
l 
L
in
e
s 
GSE3529  MDAMB231 N/A Affy U133A Rae et al. 2005  
131 (Expression Project 
for Oncology expO) 
11/120 
14 Colon 2/10 
C
o
n
tr
o
l 
M
u
lt
ip
le
 
T
is
su
e 
T
y
p
e
s 
GSE2109 
7 Ovary  3/4 
Affy U133 Plus 
2.0 
www.intgen.org 
 
2.2.2 Normalization 
Gene expression signal calculation was based upon the perfect match values from each 
probe set as previously described (Ertel et al., 2006). The datasets were normalized 
separately by computing the Robust Multichip Average (RMA) (Irizarry et al., 2003; 
Bolstad et al., 2003) directly from the affymetrix .CEL files all samples. The default 
options of RMA (with background correction, quantile normalization, and log 
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transformation) were used throughout the analysis. Quantile normalization method 
utilizes data from all arrays in an experiment in order to form the normalization relation 
(Irizarry et al., 2003; Bolstad et al., 2003). RMA generated expression measure is on the 
log base 2 scale. 
 
2.2.3 Significance Analysis of Microarray (SAM) 
Significance Analysis of Microarray (SAM) (Tusher et al., 2001) was implemented to 
identify genes that had statistically significant differences in expression between non-
relapse and relapse samples in the datasets. We performed pairwise comparisons using 
the open source software SAM Excel plug in (Tusher et al., 2001). Non-relapse versus 
relapse pairwise comparisons of samples from datasets GSE1456 and GSE2034 were 
independently analyzed, and the resulting SAM gene lists were compared to identify 
significantly up- and down- regulated genes common to both SAM lists. SAM lists for 
different breast cancer datasets differ in general to a great extent when the false discovery 
rate is set for each dataset equal to or close to zero. SAM was performed across all 
datasets comparing non-relapse versus relapse cases. 
 
2.2.4 Identification of Enriched Pathways 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (Kanehisa et al., 1997; 
2000) was used to identify enriched pathways by performing a functional enrichment 
analysis on SAM (Tusher et al., 2001) gene lists identified as significant across all breast 
cancer datasets. Global analysis was performed for overrepresented KEGG pathways 
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(Kanehisa et al., 1997; 2000), and Gene Ontology biological function, molecular function 
and cellular component
 
categories. The analysis was carried out using the Webgestalt 
system (Zhang et al., 2005) comparing significant genes obtained by SAM against all 
genes in the Affymetrix HG-U133 array, for each comparison under study using the 
hypergeometric test documented in (Zhang et al., 2005). A p-value cutoff of 0.05 was 
used in order to assess the dependence of the significant pathway identification. Up- and 
down- regulated genes were colored on the pathways using the color objects in pathways 
tool in KEGG. Genes with 1.3 fold up-regulation were labeled with red and those with 
1.3 fold down-regulation were in blue. 
 
2.2.5 Gene Set Enrichment Analysis
 
(GSEA)  
Gene set enrichment analysis
 
(GSEA) (Mootha el al., 2003; Subramanian et al., 2005) 
was used to evaluate the significance of genes upregulated in breast cancer with relapse 
within the context of the microarray data derived from non breast tumors from multiple 
tissue types (Table 1). GSEA uses predetermined gene sets and modules, to construct 
ranked lists of genes based on the correlation between expression and survival outcome 
information. We computed a ranked list of the genes in our gene subset, as reported in 
various experimental papers (Subramanian et al., 2005). 
 
2.2.6 Discriminant Analysis of Genesets  
Microarray data by Huang et al. (2003) (Table 1) was employed as an independent 
dataset (not used in our discovery mode) in order to determine how well the top 16 genes 
in our Table 2 (Denoted here as ALEX) distinguishes between non-relapse and relapse 
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patients. Arrays from the Huang et al. (2003) dataset were iteratively divided into 
learning sets (LS) and validation sets (VS) in a Monte Carlo cross-validation strategy 
(Molinaro et al., 2005). Learning sets and validation sets were selected randomly 100 
times from relapse and no relapse subsets so as to have equal proportions of each clinical 
outcome (ie. 1/4 non-surviving, 3/4 surviving). Learning set arrays were used for feature 
selection and to establish decision rules.  Validation set arrays were used to estimate the 
error expected when decision rules were applied to independent data.  Diagonal linear 
discriminant analysis (DLDA) was used to create a decision rule based on the expression 
values in the learning sets (Dudoit et al., 2002).  DLDA was also used in a univariate 
feature selection algorithm by selecting 16 genes from learning set data in a supervised 
manner to compare the success of our biomarker set with the corresponding success of 
univariate feature selection in predicting relapse. Results were summarized as bar graphs 
with each bar indicationg the mean percentage of error in predicting relapse for a given 
gene biomarker subset including ALEX.  Mean percentage error was calculated as 1 – 
area under the ROC curve (sensitivity vs. false positive rate) that is provided as output in 
the linear discriminant analysis.  
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2.3 Results 
 
2.3.1 Distribution of data among grade and molecular subtype 
Microarray datasets shown in Table 1 were used to identify relapse-associated gene and 
protein network motifs in breast cancer linked to clinical outcome. Clinical data on the 
association of tumor grade and molecular subtype to relapse status in datasets GSE1456 
and GSE2990-John Radcliffe are summarized in Figure 7. As expected, the percentage of 
relapsed patients was lowest in grade 1. However, percentage of relapse in grade 2 varied 
sharply from dataset to dataset. The inconsistency in correlation between tumor grade 
classifications to relapse across datasets for grade 2 patients can be attributed to the 
qualitative ways of determining grade from histological image data (Petushi et al., 2006).  
 
The GSE1456 dataset contained information on molecular subtypes in addition to grade 
(Sorlie et al., 2001) as summarized in Figure 7b. Grade 3 patients comprised an 
overwhelming majority of patients classified into molecular subtypes identified as basal, 
ERBB2, and luminal B. Percentages of patients who had relapse in these categories were 
significantly higher than the corresponding percentages of non-relapse patients. As noted 
previously by different authors, these results indicate that both tumor grade (Petushi et 
al., 2006) and molecular subtype (Sorlie et al., 2001; 2003) correlate with, but do not 
predict clinical outcome with certainty.  
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2.3.2 SAM Results for Non-Relapse Versus Relapse Comparisons 
List of significantly altered (SAM) genes between normal to tumor comparisons are often 
largely tissue specific and contain much fewer genes than the corresponding lists for 
cancer cell line to normal and cancer cell line to tumor comparisons (Ertel et al., 2006). 
In this study, SAM gene lists for non-relapse to relapse comparisons differed 
significantly among the datasets with a zero false discovery rate. In order to detect SAM 
genes common to datasets GSE1456 and GSE2034 for non-relapse and relapse 
comparison, we methodically increased the false discovery rate up to 10% and identified 
a list of 119 genes common in both datasets. This list contained 4 genes that appear as 
breast cancer associated in the Ingenuity Pathways Analysis (IPA) database (Ingenuity 
Systems, www.ingenuity.com). These genes are as follows: CCND2, CTDSPL, SFRS7, 
and TGFBR2. Next, we compared the list with the corresponding list of SAM genes for a 
third database (GSE2990) obtained by using zero false discovery rate and found that 
there were 17 genes common in both databases. These results indicate that SAM gene 
lists vary from database to database and are also dependent on the use of false discovery 
rate in their calculation. Nevertheless, as shown in the next subsection, the SAM analysis 
provides an important tool for determining significantly altered cellular pathways in non-
relapse to relapse comparison.  
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Figure 7 a) Comparison of datasets GSE1456 (Pawitan et al., 2005) and GSE2990-John 
Radcliffe (Sotiriou et al., 2006). Distribution of patients according to relapse status, 
which were, classified with tumor grades 1, 2 and 3. b) Summary of distribution of tumor 
samples in GSE2990-John Radcliffe, of the five molecular subtypes, classified as tumor 
grades 1, 2 and 3, and c) distribution of patients with relapse versus non-relapse 
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characterized according to molecular subtypes: basal, ERBB2, luminal A, luminal B and 
normal-like.  
 
2.3.3 Significantly Altered Pathways in Non-Relapse to Relapse Comparison 
We determined SAM lists for each dataset separately using zero false discovery rates and 
used these lists in hypergeometric tests for identifying significantly enriched KEGG 
pathways. Results shown in Figure 8 indicate that KEGG pathways for focal adhesion 
(hsa04510), mitogen-activated protein kinase (MAPK) signaling (hsa04010), and 
cytokine-cytokine receptor interaction (hsa04060) are typically upregulated in breast 
cancer patients with relapse compared to breast cancer patients with non-relapse. These 
three pathways contained a large number of genes that were previously associated with 
cancer (Ertel et al., 2006).  
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Figure 8 Enriched KEGG pathways. 
 
Next, we determined the fold changes for non-relapse to relapse comparison for genes 
present in the MAPK, cytokine-cytokine receptor interaction, and focal adhesion 
pathways. The three enriched KEGG pathway diagrams shown in Figures 9 indicate the 
genes that are upregulated (more than 1.3 fold) in red and genes downregulated (less than 
0.8) in blue between non-relapse and relapse samples in GSE1456 dataset. The list of 
upregulated genes in the diagrams contained a large number of extracellular proteins, 
some of which, such as EGFR, are considered in antibody vaccination studies for breast 
cancer therapy (Adams and Weiner, 2005). Extracellular proteins are easily identified and 
their concentration can be quantified in the excised tumor and the blood serum using 
various proteomic techniques. 
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Table 2 List of genes that belong in the cytokine-cytokine receptor interaction, focal adhesion and MAPK signaling pathways that 
were found to be upregulated in at least 5 out of the 16 comparisons between non-relapse and relapse (grade 1, grade 2, grade 3 and all 
samples). Highlighted in bold are SAM genes. 
Gene Symbol Gene Title 
Entrez 
ID 
All samples 
(of 5) 
Grade 1 
(of 3) 
Grade 2 
(of 3) 
Grade 3 
(of 3) 
Cell 
Lines 
(of 2) 
GO Cellular 
Compartment 
BCL2 B-cell CLL/lymphoma 2 596 5 1 2 3 1 nucleus, mitochondrion 
TGFB1 transforming growth factor, beta 1  7040 5 2 3 2 2 extracellular 
SOS1 son of sevenless homolog 1 (Drosophila) 6654 5 2 2 1 2 intracellular 
EGFR epidermal growth factor receptor 1956 4 3 3 3 2 extracellular, nucleus 
NR4A1 nuclear receptor subfamily 4, group A, member 1 3164 4 1 3 3 1 nucleus 
IL1B interleukin 1, beta 3553 4 1 2 3 2 extracellular 
MEF2C MADS box transcription enhancer factor 2 4208 4 1 2 3 1 nucleus 
JUND jun D proto-oncogene 3727 4 0 2 3 1 nucleus 
CCL2 chemokine (C-C motif) ligand 2 6347 4 2 1 3 2 extracellular,  membrane 
MAX MYC associated factor X 4149 4 2 3 2 1 nucleus 
FASLG Fas ligand (TNF superfamily, member 6) 356 4 2 2 2 0 extracellular,  membrane 
CXCL11 chemokine (C-X-C motif) ligand 11 6373 4 2 1 2 2 extracellular 
IL15 interleukin 15 3600 4 2 1 2 2 extracellular, membrane 
CCL18 chemokine (C-C motif) ligand 18 6362 4 2 1 2 1 extracellular 
IL23A interleukin 23, alpha subunit p19 51561 4 2 1 2 1 extracellular 
CX3CL1 chemokine (C-X3-C motif) ligand 1 6376 4 0 0 2 1 extracellular,  membrane 
IL12B interleukin 12B (p40) 3593 4 2 1 1 2 extracellular,  membrane 
FGF1 fibroblast growth factor 1 (acidic) 2246 3 2 3 3 2 extracellular, membrane 
HGF hepatocyte growth factor (hepapoietin A; scatter factor) 3082 3 2 3 3 2  --- 
CSF1 colony stimulating factor 1 (macrophage) 1435 3 2 2 3 2 extracellular, membrane 
FLT3LG fms-related tyrosine kinase 3 ligand 2323 3 2 2 3 2 extracellular, membrane 
IL1A interleukin 1, alpha 3552 3 2 2 3 2 extracellular 
BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) 655 3 2 2 3 1 extracellular 
CNTF ciliary neurotrophic factor 1270 3 2 2 3 1 extracellular 
EDA ectodysplasin A 1896 3 1 2 3 2 membrane, cytoplasm  
IL11 interleukin 11 3589 3 2 2 3 1 extracellular 
IL4 interleukin 4 3565 3 2 2 3 1 extracellular 
INHBC inhibin, beta C 3626 3 2 2 3 1 extracellular 
JUN v-jun sarcoma virus 17 oncogene homolog (avian) 3725 3 1 2 3 2 nucleus 
TNFSF7 tumor necrosis factor (ligand) superfamily, member 7 970 3 2 2 3 1 extracellular, membrane 
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Gene Symbol Gene Title (Continued) 
Entrez 
ID 
All samples 
(of 5) 
Grade 1 
(of 3) 
Grade 2 
(of 3) 
Grade 3 
(of 3) 
Cell 
Lines 
(of 2) 
GO Cellular 
Compartment 
TNF tumor necrosis factor (TNF superfamily, member 2) 7124 3 1 2 3 1 extracellular, membrane 
CXCL12 chemokine (C-X-C motif) ligand 12  6387 3 1 2 3 0 Extracellular 
IL12A interleukin 12A ( p35) 3592 3 2 1 3 1 Extracellular 
IL6 interleukin 6 (interferon, beta 2) 3569 3 1 1 3 2 Extracellular 
CXCL5 chemokine (C-X-C motif) ligand 5 6374 3 1 1 3 1 Extracellular 
CXCL2 chemokine (C-X-C motif) ligand 2 2920 3 0 1 3 1 Extracellular 
CCL22 chemokine (C-C motif) ligand 22 6367 3 2 3 2 1 Extracellular 
IL9 interleukin 9 3578 3 2 3 2 1 Extracellular 
IL21 interleukin 21 59067 3 2 3 2 0 Extracellular 
CCL11 chemokine (C-C motif) ligand 11 6356 3 2 2 2 1 Extracellular 
ELK1 ELK1, member of ETS oncogene family 2002 3 2 2 2 1 Nucleus 
TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 8995 3 2 2 2 1 extracellular, membrane 
TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 8744 3 1 2 2 2 extracellular, membrane 
CCL17 chemokine (C-C motif) ligand 17 6361 3 1 2 2 1 Extracellular 
CCL20 chemokine (C-C motif) ligand 20 6364 3 1 2 2 1 Extracellular 
CCL5 chemokine (C-C motif) ligand 5 6352 3 2 2 2 0 Extracellular 
TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 8600 3 1 2 2 0 extracellular, membrane 
CXCL10 chemokine (C-X-C motif) ligand 10 3627 3 2 1 2 1 Extracellular 
IL7 interleukin 7 3574 3 2 1 2 1 Extracellular 
PDGFC platelet derived growth factor C 56034 3 2 1 2 1 Membrane 
CXCL9 chemokine (C-X-C motif) ligand 9 4283 3 2 1 2 0 Extracellular 
BMP2 bone morphogenetic protein 2 650 3 3 0 2 1 Extracellular 
CXCL13 chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) 10563 3 1 0 2 0 Extracellular 
CXCL6 chemokine (C-X-C motif) ligand 6  6372 3 0 0 2 1 Extracellular 
MAPK1 mitogen-activated protein kinase 1 5594 3 2 2 1 2  --- 
IL3 interleukin 3 (colony-stimulating factor, multiple) 3562 3 2 2 1 0 Extracellular 
RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 5894 3 0 1 1 1 
mitochondrial outer 
membrane 
LIF leukemia inhibitory factor (cholinergic differentiation factor) 3976 3 0 1 1 0 Extracellular 
MAP2K1 mitogen-activated protein kinase kinase 1 5604 3 1 0 1 1  --- 
CCL27 chemokine (C-C motif) ligand 27 10850 3 1 2 0 2 Extracellular 
BAD BCL2-antagonist of cell death 572 3 0 2 0 1 Cytoplasm 
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Figure 8 KEGG pathways: a) MAPK pathway, b) Focal Adhesion, and c) Cytokine-
cytokine interaction pathway. Gene expression shifts are projected from comparisons of 
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non-relapse to relapse comparisons for samples classified by tumor grade in GSE1456. 
The color red indicates upregulated genes; and blue indicates downregulated genes. 
 
2.3.4. Changes in ECM Gene Expression and Relapse in Cancer 
Genes that are consistently up- or down- regulated in multiple datasets are shown in the 
form of a heat map in Figure 10 for MAPK signaling cascade. Columns in this figure 
indicate the set of data for non-relapse versus relapse comparisons and rows indicate 
genes at the input and output of MAPK pathway. Similar diagrams for cytokine-cytokine 
receptor interaction and focal adhesion KEGG pathways were produced (not shown) and 
were used to determine a subset of genes that were consistently upregulated in at least 
three out of the five microarray datasets used in the analysis. This list is shown in Table 3 
and contains 61 genes 47 of which code for ECM or ECM interacting membrane 
proteins. Seven genes in this list, BCL2, CSF1, EGFR, IL12A, IL12B, JUN, and TGFB1, 
are also listed as breast cancer related in the Ingenuity Pathway Analysis (IPA) database 
(Ingenuity Systems, www.ingenuity.com). Using the publicly-available knowledge base 
HUPO Plasma Proteome Project (PPP; www.bioinformatics.med.umich.edu/hupo/ppp) 
(Omenn et al., 2005) we identified 20 genes in Table 2 present in serum. These genes are 
as follows: EGFR, CXCL2, IL1A, FASLG, IL7, INHBC, MEF2C, PDGFC, BAD, RAF1, 
IL21, BCL2, CCL20, CXCL6, CXCL11, CXCL5, CXCL12, SOS1, TGFB1, and TNF. 
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Figure 9 A module-map showing the direction of regulation of genes in MAPK pathway 
and the color red indicates an upregulated gene, and the color blue indicates a 
downregulated gene. 
 
2.3.5 Mean Error in Predicting Relapse with ALEX and Other Biomarker Subsets 
 
We used an independent microarray dataset on breast cancer patients to assess the relapse 
prediction potential of our gene set ALEX (the top 17 genes in Table 2). About ¼ of the 
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patients in the dataset by Huang et al. (2003) had relapse during the five years after 
treatment. We computed mean error rate for predicting relapse using three different 
biomarker sets (16 gene ALEX, 16 gene ODX (Paik et al., 2004), and 33 gene SHEN 
(Shen et al., 2004) and compared it to the prediction of a 17 gene subset (UR) selected by 
univariate feature selection (Dudoit et al., 2007). Figure 10 shows the mean error in 
identifying relapse patients with relapse with different sets of biomarkers. The graph 
shows univariate feature selection with minimum error in estimating relapse; however, 
this is not surprising since the same dataset was used for learning and validation. Our 
gene subset ALEX does slightly worse than UR but better than ODX and SHEN. Taken 
together with the fact that majority of the genes in the ALEX set code for extracellular 
proteins whose presence in serum can be measured. 
 
Figure 10 Percentage error of predicting relapse patients using ALEX and other 
biomarker sets.  
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2.3.6 Gene Set Enrichment Analysis for Predicting Relapse in Solid Tumors 
Next we wanted to see whether a subset of the genes listed in Table 2 also signified 
relapse in cancers originating from other organs and tissues. For this purpose, we created 
a control microarray dataset of multiple tumors shown in Table 1 and used GSEA 
(Mootha el al., 2003; Subramanian et al., 2005) to evaluate genes found to be primarily 
upregulated (Table 2) on data other than breast tumor, derived from multiple tissue-type 
tumors (Table 1). The ranking results indicated in Table 3 indicate that protein products 
for genes such as EGFR, IL12B, INHBC, IL12A, IL9, TNF, TNFSF9, and IL4 are 
potential biomarker candidates for relapse in most solid tissue types. The list also 
contains in its top twenty other malignancy associated biomarkers such as TNSF18, IL21, 
JUN, and TGFB1.  
 
2.3.7 Relevance of Breast Cancer Cell Lines to Research on Molecular Mechanisms 
of Relapse in Cancer  
Our computations shown in Table 3 indicated that much of the same genes that are 
upregulated in breast cancer relapse were also upregulated in highly invasive breast 
cancer cell lines (BT474, MDAMB231) when compared to poorly invasive MCF7 cell 
line (Ertel et al., 2006). For example, genes TGFB1, SOS1, EGFR, CCL2, CXCL11, 
IL1A, IL1B, IL6, IL12B, IL15, FGF1, HGF, CSF1, FLT3LG, EDA, MAPK1, TNSF9, 
and CCL27 are upregulated consistently in MCF7 to MDAMB231 and MCF7 to BT474 
comparisons. These genes and their protein products constitute a set of potential 
biomarkers for predicting relapse from the molecular anatomy of the excised breast 
tumor. Although cancer cell lines differ between normal and cancer tissue to a great 
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extent in global gene expression profiles of metabolic pathways (Ertel et al., 2006), 
results in this study indicate the potential usefulness of cancer cell lines in developing 
biomarkers for cancer relapse.  
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Table 3 Top thirty genes using GSEA based on the correlation between their expression and the class distinction in multiple tumor types. 
All tumor 
types 
Only 
Colon 
Only 
Ovary 
Gene 
Symbol 
Gene Title Entrez ID GO Biological Process 
1 5 15 EGFR epidermal growth factor receptor 1956  cell cycle  
2 19 21 IL12B interleukin 12B (p40) 3593  regulation of cytokine biosynthesis  
3 2 22 INHBC inhibin, beta C 3626  --- 
4 37 2 IL12A interleukin 12A (p35) 3592  immune response  
5 8 10 IL9 interleukin 9 3578  cell-cell signaling  
6 14 30 TNF tumor necrosis factor (TNF superfamily, member 2) 7124  anti-apoptosis  
7 6 5 TNFSF9 tumor necrosis factor (ligand) superfamily, member 9 8744  signal transduction  
8 17 9 IL4 interleukin 4 3565  chemotaxis  
9 21 23 TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 8995  anti-apoptosis  
10 18 29 IL21 interleukin 21 59067  signal transduction  
11 11 32 CSF1 colony stimulating factor 1 (macrophage) 1435  cell proliferation  
12 20 12 JUN v-jun sarcoma virus 17 oncogene homolog (avian) 3725  transcription  
13 12 19 CCL22 chemokine (C-C motif) ligand 22 6367  chemotaxis  
14 26 4 CCL27 chemokine (C-C motif) ligand 27 10850  chemotaxis  
15 1 13 TGFB1 transforming growth factor, beta 1 7040  regulation through cell cycle  
16 32 25 ELK1 ELK1, member of ETS oncogene family 2002  transcription  
17 33 17 TNFSF11 tumor necrosis factor (ligand) superfamily, member 11 8600  immune response  
18 9 8 IL3 interleukin 3 (colony-stimulating factor, multiple) 3562  immune response  
19 25 16 SOS1 son of sevenless homolog 1 (Drosophila) 6654  signal transduction  
20 23 7 IL23A interleukin 23, alpha subunit p19 51561  immune response  
21 42 45 IL6 interleukin 6 (interferon, beta 2) 3569  neutrophil apoptosis  
22 38 40 CCL17 chemokine (C-C motif) ligand 17 6361  chemotaxis  
23 16 33 IL7 interleukin 7 3574  immune response  
24 45 31 CNTF ciliary neurotrophic factor 1270  signal transduction  
25 43 20 PDGFC platelet derived growth factor C 56034  lipid metabolism  
26 15 27 EDA ectodysplasin A 1896  phosphate transport  
27 47 24 IL11 interleukin 11 3589  cell-cell signaling  
28 35 1 LIF leukemia inhibitory factor (cholinergic differentiation factor) 3976  immune response  
29 30 38 IL1B interleukin 1, beta 3553  regulation through cell cycle  
30 31 28 BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) 655  cell differentiation  
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2.4 Discussion 
In this investigation, we used four different microarray breast cancer datasets obtained by 
using the Affymetrix platform (Wang et al., 2005; Sotiriou et al. 2006; Pawitan et al. 
2005) and an additional cDNA dataset (Sorlie et al., 2003) in order to identify molecular 
mechanisms that differentiate relapse from non relapse. As was previously observed in 
microarray data analysis (Subramanian et al., 2005), significance analysis of microarrays 
(Tusher et al., 2001) determined for each of the microarray datasets under consideration a 
different list of significantly altered genes. Nevertheless these separate lists converged in 
the determination of cellular pathways enriched in relapse.  
 
Most frequently enriched KEGG pathways in the microarray datasets under consideration 
were focal adhesion, MAPK signaling, and cytokine-cytokine receptor interaction. Our 
data analysis further showed that these three pathways were significantly enriched for 
relapse in all three grades of breast cancer and molecular subtypes. These pathways were 
also significantly enriched in a dataset that compared microarray data from ductal 
carcinoma in situ (DCIS) regions of breast tumors with the invasive ductal carcinoma 
(IDC) regions of the same tumors (Schuetz et al., 2006). The sum total of these results 
indicated the potential of genes in these pathways effective biomarkers of relapse in 
breast cancer. Further analysis of microarray data for breast cancer cell lines (Minn et al. 
2005; Rae et al. 2005) also pointed to these pathways as significantly enriched for poorly 
invasive to highly invasive comparison, suggesting that breast cell lines could be useful 
in the investigation of the molecular mechanisms of relapse in breast cancer.  
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A recent study by Shen et al. (2004) used a Bayesian two-stage mixture approach to 
derive an inter-study validated meta-signature associated with breast cancer relapse and 
survival. The 90 gene meta-signature derived by these authors classified 122 patients into 
a high risk group, where 84 (69%) of them had a recurrence. Shen et al. (2004) also 
examined whether a particular gene ontology (GO) category was enriched in the 
recurrence signature. Each of the ninety genes were mapped to Gene ontology (GO) 
terms and then grouped by functional classes. The top seven enriched functional groups 
in the meta-signature included GO categories involving cell cycle regulation, signal 
transduction, signaling pathways that regulate cell growth (VEGF, PPP2R5C), immune 
response (TRAF3), and apoptosis (SFRP4). Our own analysis presented in this article 
also finds these GO categories to be enriched in at least 2 out of 5 databases based on 
SAM gene lists obtained independently for each microarray dataset. These results 
indicate that two approaches for analysis of multiple microarray datasets have the 
potential to yield common signature patterns in functional classification.  
 
Next we searched for relapse associated patterns in the altered use of cellular pathways 
that play a role in breast cancer. We focused on the three pathways enriched in relapse 
subgroup (MAPK signaling, focal adhesion and cytokine mediated communication 
pathways) and determined expression patterns of the gene set whose protein subunit 
products comprised the nodes of these pathways. Three genes in this set (TGFB1, BCL2, 
and SOS1) were consistently upregulated in relapse patients in the five microarray 
datasets used in the study. A set of 14 genes belonging to MAPK signaling, focal 
adhesion or cytokine-cytokine receptor interaction pathways (CCL2, CXCL11, CX3CL1, 
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EGFR, FASLG, IL1B, IL12B, IL15, IL23A, JUND, MAX, MEF2C, CCL18, NR4A1) 
were consistently upregulated in relapse compared to non-relapse in four of the five 
microarray datasets. Ten out of fourteen coded for extracellular proteins or their 
membrane receptors and four coded for nuclear proteins. Forty four genes in the three 
enriched pathways were upregulated in relapse in three out of the five microarray 
databases. Protein subunit products of approximately 90% of these genes occupied 
extracellular space and many of them were previously shown to be expressed as serum 
proteins. The genes observed to have mostly upregulated gene expression patterns 
between non-relapse and relapse were primarily located at the start and end of signaling 
pathways: extracellular proteins and transcription factors. 
 
A subset of the genes in the set shown in Table 2 has already been implicated in cancer. 
A polymorphism in the TGFB1 gene was previously associated with breast cancer in 
women aged 65 or older (Ziv et al., 2001). More recent research implicates SNP 
variations of TGFB1 as biomarkers of breast cancer relapse (Kaklamani et al., 2005; 
Pharoah et al., 2006). BCL2 proteins are inhibitors of the mitochondrial apoptosis 
pathway and were shown to reduce the effectiveness of chemotherapy (Emi et al., 2006). 
BCL2 has long been recognized as associated with cancer relapse, however, neither the 
presence nor the absence of its expression on breast histology slides could predict 
disease-free survival or overall survival in patients with breast cancer (Alsabeh et al., 
1996). SOS1 is involved in the regulation of cell growth and differentiation and has been 
identified as part of a panel of tumor-associated antigens from breast carcinoma cell lines 
(Pavoni et al., 2004). Activity of EGFR was shown to be critical to cellular proliferation, 
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differentiation, and survival (Herbst et al., 2002; Baselga et al., 2000). Recent studies 
have focused on selectively targeting solid tumor cell surface proteins and ligands using 
vaccine-like anti-epidermal growth factor receptor therapy (Adams and Weiner, 2005).  
 
Other genes in this list, such as interleukins have been found to be linked to with anti-
inflammatory properties that are essential to a normal physiology (Keller et al., 1996; 
Trikha et al., 2003). In a study by Hussein et al., it was found that increased serum levels 
of IL-6 and IL-12 are correlated to progression of breast cancer tumors and it was 
suggested that they could be used in non-invasive assays for tumor progression in breast 
cancer patients (Hussein et al., 2004). Upregulation of IL-6 was shown to promote cancer 
growth, metastasis, and was associated with poor prognosis and shortened survival 
(Belluco et al., 2000; Shariat et al., 2001; Trikha et al., 2003; Wei et al., 2003) in patients 
with solid tumors including melanoma and carcinoma of the breast, colon and rectum, 
kidney, lung, ovary, pancreas, prostate, and stomach (Trikha et al., 2003). In addition to 
being a possible target for therapy, published preclinical and clinical data associates IL-6 
expression to angiogenesis, metastasis as well as drug resistance (Nakashima et al., 2000; 
Smith et al., 2001; Alas et al., 2003; Zerbini et al., 2003). Elevated serum IL-6 
concentrations have been associated with poor prognosis in a variety of cancers, and 
decreases in serum IL-6 concentrations have been reported after chemotherapy (Jiang et 
al., 2000). 
 
Chemokines such as CXCL12 appear to be expressed in higher levels in node-positive 
than in node-negative tumors; in tumors that metastasized, and tumors from patients who 
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died compared to those that survived (Kang et al., 2005). Jun has been implicated in the 
regulation of cell proliferation and cell cycle progression (Kovary and Bravo, 1991; 
Smith and Prochownik, 1992; Behre et al., 1999; 1999; 1999; Schreiber et al., 1999; 
Wisdom et al., 1999) and has been widely studied for its role in differentiation (Vangala 
et al., 2002). Likewise, upregulation of MEF2C has been linked to breast cancer invasion 
(Schuetz et al., 2006). Taken together these results indicate the potential of combined 
analysis of microarray data from a multitude of laboratories in the identification of 
biomarkers for breast cancer relapse.  
 
The gene list in Table 2 may be potentially useful in selecting biomarkers for relapse in 
cancers with solid tumors. Further analysis of the gene set presented in Table 2 with the 
gene set enrichment tool yielded of ranked gene list (Table 3) that appeared to correlate 
with relapse in a wide variety of cancers listed in Table 1. These results suggest potential 
genes involved in cell communication and signaling pathways as determinants or 
biomarkers of relapse in cancer. The gene list in Table 2 includes a multitude of genes 
with potential roles in cancer cell signaling, signal transduction, cell division cycle, anti-
apoptosis, proliferation, DNA repair, hypoxia, and immune response and it is possible 
that a subset of these also indicate disease states other than cancer such as hypertension, 
cardiac inflammation, and viral infection. Future work on the systemic and local 
expressions of protein subunit coded by these genes, combined with pattern recognition 
techniques hold the promise of discovering novel biomarkers for relapse and cancer 
vaccines  that would aim to treat an existing cancer or even to prevent it from occurring. 
Although there are currently no therapeutic vaccines on the market, they could be 
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developed to have potentially tumor growth limiting abilities by increasing the patient’s 
immune response.  
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CHAPTER 3: Heterogeneous Breast Tumoroids: An In Vitro Assay for 
Investigating Cellular Heterogeneity and Drug Delivery 
 
Summary 
This chapter presents my work on the development of heterogeneous breast tumoroids 
using an in vitro assay for investigating cellular heterogeneity and drug delivery. This is a 
collaborative effort, and the chapter was recently published in the Journal of 
Biomolecular Screening (Vamvakidou et al., 2007 I). Breast tumors are typically 
heterogeneous and contain diverse subpopulations of tumor cells with differing 
phenotypic properties. Planar cultures of cancer cell lines are not viable models of 
investigation of cell-cell and cell-matrix interactions during tumor development. This 
article presents an in vitro coculture-based three-dimensional heterogeneous breast tumor 
model that can be used in drug resistance and drug delivery investigations. Breast cancer 
cell lines of different phenotypes (MDAMB231, MCF7 and ZR751) were cocultured in a 
rotating wall vessel (RWV) bioreactor to form a large number of heterogeneous 
tumoroids in a single cell culture experiment. Cells in the rotating vessels were labeled 
with CellTracker fluorescent probes to allow for time-course fluorescence microscopy to 
monitor cell aggregation. Histological sections of tumoroids were stained with 
hematoxylin and eosin (H&E), progesterone receptor (PR), E-cadherin (E-cad) and 
proliferation marker, ki67. In vitro tumoroids developed in this study recapture important 
features of the temporal-spatial organization of solid tumors, including the presence of 
necrotic areas at the center and higher levels of cell division at the tumor periphery. E-cad 
positive MCF7 cells form larger tumoroids than E-cad negative MDAMB231 cells. In 
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heterogeneous tumors, the irregular surface roughness was mainly due to the presence of 
MDAMB231 cells whereas MCF7 cells formed smooth surfaces. Moreover, when 
heterogeneous tumoroids were placed onto collagen gels, highly invasive MDAMB231 
cell rich surface regions produced extensions into the matrix whereas poorly invasive 
MCF7 cells did not. The fact that one can form a large number of 1 mm size tumoroids in 
one coculture, attest to the potential use of this system at high throughput investigations 
of cancer drug development and drug delivery into the tumor. 
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3.1 Introduction 
Breast tumors are biologically heterogeneous in that they are composed of numerous 
tumor-cell subpopulations (Kang et al., 2000). In the present study we have cocultured 
breast cell lines of different invasive potentials and developed large numbers of 
heterogeneous tumoroids of about 1 mm in diameter in a rotating wall vessel (RWV) 
bioreactor. Breast cell lines have varying phenotypic characteristics including 
morphology, growth rate, invasive potential and drug sensitivity (Fidler, 1978). As such, 
they provide a model system to study the molecular and genetic basis of tumor growth, 
but when cell lines are used in monocultures, they fail to capture the presence of cancer 
cells of different phenotypes in a breast tumor. Tumor heterogeneity is evident from 
distinct cellular and molecular properties of primary tumor subpopulations such as 
receptor status, ploidy, tumor cell growth, and hormone dependency (Thompson et al., 
1992). 
 
Tumor malignancies progresses through variable stages and in some cases, with time 
acquire an invasive potential (Thiery et al., 1999). Tumor progression has been associated 
with decreased genomic stability, oncogene and tumor-suppressor gene expression 
changes, and loss of DNA repair mechanisms within the cells (Cairns et al., 1975; Nowell 
et al., 1976; 1986; Devilee and Cornelisse, 1994). Existence of multiple cell 
subpopulations was shown to be correlated with the process of tumor growth and 
sensitivity to chemotherapy (Sevin and Perras, 1997), radiation therapy (Britten et al., 
1996), immunotherapy (Fleuren et al., 1995), and hormone therapy (Woo et al., 1991).  
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Tumor heterogeneity is modulated by the microenvironment with regards to hypoxia, 
metabolism, and nutrient supply limitations (Skoyum et al., 1997; Heppner and Miller, 
1998). Interactions of subpopulations are expected to play a significant role in growth and 
behavior within a tumor’s architecture (Aabo et al., 1996). As time progresses, certain 
subpopulations of a breast tumor may dominate other cells in heterogeneous tumors 
(Price et al., 1990). This phenomenon, also referred to as clonal dominance, has been 
observed in many studies, and is thought to result from altered growth kinetics of 
subpopulations in solid tumors (Price et al., 1990; Starolesky et al., 1990; 1992; Samiei 
and Waghorne, 1991; Aabo et al., 1995). An in vitro tumor model capable of sustaining 
long term culture of heterogeneous cell populations could be a powerful tool for 
investigating the influence of subpopulation diversity on tumor invasive potential. 
 
Three-dimensional monoculture and coculture models have been used in studies with 
varying applications such as angiogenesis, differentiation and metastasis (Bartholoma et 
al., 2005; Yui et al., 2005; Wegner et al., 2005; Barett et al., 2005; Rhee et al., 2001; 
Starzec et al., 2003; dit Faute et al., 2002; Zhang et al., 2005; Furbert-Harris et al., 2003; 
Schuster et al., 1994). A three-dimensional coculture model combined prostate cancer 
cell lines with bone cells to investigate metastatic potential, progression and metastasis to 
bone (Wilson et al., 1989). Using these publications as a foundation, we have developed a 
high throughput heterogeneous tumor model that has the potential to represent the 
behavior of early stage tumors in vivo. The three-dimensional tumoroid model presented 
in this study recaptures important features of the temporal-spatial organization of solid 
tumors, including the presence of necrotic areas in the center (Hall et al., 1990) and the 
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preferential location of invasive cell types close to the tumoroid surface. The high 
throughput production of in vitro tumor models will accelerate early stage drug 
development and drug delivery studies. 
 
 49 
3.2 Materials and Methods 
 
3.2.1 Cell Culture 
The human breast cell lines used in this study (MDAMB231, MCF7 and ZR751) were 
obtained from American Type Culture Collection (ATCC). These cell lines were 
maintained at 37˚C, 95% relative humidity and 5% CO2 and cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Biowhittaker, Walkersville, MD), 
supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT). The cancer 
research literature describes MCF7 and ZR751 as non-invasive (Thomspon et al., 1992) 
estrogen receptor (ER), progesterone receptor (PR), and E-cadherin (E-cad) positive 
(Fabbro et al., 1986; Hiraguri et al., 1998; Engel et al., 1978) whereas MDAMB231 cell 
line has been characterized as a highly invasive (Thomspon et al., 1992), ER, PR and E-
cad negative (Pierceall et al 1995). 
 
2.2.2 Development of Tumoroids 
Aggregation experiments described here were performed using a rotating wall vessel 
(RWV) bioreactor (10 ml disposable High Aspect Ratio Vessel, HARV, Synthecon Inc., 
Houston TX). The RWV was sterilized with 0.1N NaOH and exposed to UV for 20 
minutes on each side (Lelkes and Unsworth, 2002). The RWV was rinsed 3 times with 
Ca
2+/
Mg
2+
 free phosphate buffered saline (PBS, Cellgro) and filled with fresh medium 
(Lelkes and Unsworth, 2002). Cell cultures were initiated by seeding 0.2 × 10
6
 cells per 
ml in a 10 ml RWV. Labeled cells of the three cell types were seeded in the vessel at 
predetermined cell densities in order to assess the extent of heterogeneity in the resulting 
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tumoroids. Prior to each experiment, cells were trypsinized using Trypsin:EDTA, 
counted and labeled. Cell labeling was performed using CellTracker Probes (Molecular 
Probes, Eugene, OR); CellTracker Green CMFDA (C2925), CellTracker Blue CMAC 
(C2110) and CellTracker Red CMTPX (C34452), which are fluorescent probes that are 
retained in living cells through several generations. CellTracker reagents were loaded into 
cells by adding the reagent to serum free RPMI-1640 culture medium and then washed 
briefly with fresh medium. The vessels were routinely checked for possible 
contamination, air bubbles, and vessel leakage. Initially, the vessels were set to rotate at 
12-rpm in a 37˚C incubator with 5% CO2. This rpm setting allowed us to avoid frequent 
crashes of the cell aggregates with the vessel walls (Lelkes and Unsworth, 2002). 
 
3.2.3 Determination of the Size Distribution of Aggregates 
Images of in vitro tumoroids on the planar surface of the vessel were captured at discrete 
time points using a phase contrast microscope and a fluorescent microscope (Leica 
DMRX, Wetzlar, Germany). The size distribution of tumoroids in the RWV was 
computed from these images using standard imaging software (ImageJ, NIH).  
 
3.2.4 Determination of Cellular Composition 
Following culture in the RWV, the cell suspension was passed through a 40 µm mesh 
(BD Falcon, San Jose, CA), to separate single cells from aggregates. Aggregates were 
then collected and subsequently dispersed by treatment with trypsin:EDTA. The resulting 
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single-cell suspension was counted by time-course fluorescent microscopy using red and 
green CellTracker fluorescent probes. 
 
3.2.5 Histology Evaluation 
A representative sample of tumoroids per cell line composition was processed for routine 
histology by fixing them in 10% neutral buffered formalin (Formalde-Fresh, Fisher) and 
embedding them in paraffin. The embedded tumoroids were sectioned at 10 µm intervals, 
deparaffinized in xylene, and processed through a graded series of alcohol 
concentrations. Serial sections were prepared and stained using hematoxylin and eosin 
(H&E) (Fisher), as well as progesterone receptor (PR), E-cadherin (E-cad) and 
proliferating marker ki67, and samples were examined using Coolscope scanner VS 
Digital Microscope (Nikon Corporation., Ltd.). 
 
3.2.6 Implantation and Evaluation of Migration Potential 
For studies involving tumoroid-extracellular matrix interactions, coculture tumoroids 
were implanted into three-dimensional collagen I gels after being cultured in the RWV 
for 10 days. A collagen solution was prepared consisting of 1 mg/ml rat tail collagen type 
I solution (BD Biosciences) and was added to 12-well plates. The tumoroids were mixed 
into the gel using a pipette. Cell invasion into the matrix was recorded after 24 hours at 
37˚C in a humidified incubator of 5% CO2, using an inverted phase contrast light and 
fluorescent microscope. 
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3.2.7 Statistical Analysis 
All values are reported for triplicate cultures and expressed as means and standard 
deviation (SD) of the mean. Statistical significance was assessed using student t-test, and 
p < 0.05 was considered statistically significant. Uncertainties in measurement of cell 
aggregates must be considered. Sources of uncertainty include loss of the spherical shape 
of the cellular aggregates and the effects of periodic changes in the culture medium, 
amongst others. 
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3.3 Results 
 
3.3.1 Coculture Model 
MCF7, MDAMB231 and ZR751 cells aggregated together in the RWV to form 
heterogeneous tumoroids that were similar in shape and size to homogeneous tumors 
reported in the literature (Kelm et al., 2003). Shown in (Figure 11a) is a 24 hours post 
seeding coculture aggregate composed of 1:1:1 concentration ratio of the three cancer cell 
lines. Fluorescent microscopy clearly shows the coculture of multiple cell types aggregate 
in groups or singles. In particular MDAMB231 cells, labeled red, appear to be closer to 
the periphery of the in vitro cell aggregate (Figure 11b). These results indicate that it is 
feasible to develop heterogeneous breast tumoroid models using a combination of breast 
cancer cell lines. 
 
 
Figure 11 Day 1 cell aggregate of 1:1:1 coculture of MDAMB231, ZR751 and MCF7 
breast cancer cells formed in the RWV. a) Image taken using phase contrast microscopy. 
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b) Fluorescent labeling of the three cell lines reveals spatial distribution, where the least 
aggressive cell line (blue: MCF7) is located in the center, and the most aggressive (red: 
MDAMB231) at the periphery. Bar: 30 µm 
 
3.3.2 Time-Course of Tumoroid Evolution 
The following experiments focus on homogeneous tumoroids and heterogeneous 
tumoroids composed of two cell lines of highly different invasive potential: MCF7 and 
MDAMB231 cells. Homogeneous tumoroids composed of MDAMB231 cells form small 
aggregates of 50-100 µm, 24 hours post seeding (Figure 12a, Figure 13a). Subsets of 
these aggregates develop into steadily growing tumoroids by doubling their size by day 6 
(Figure 12a). Tumoroids composed of only MCF7 cells exhibit a rapid aggregation phase, 
particularly after day 2 (Figure 12b, Figure 13a). Phase contrast images of MCF7 cell 
aggregates show that these tumoroids are more compact and dense than the MDAMB231 
cell aggregates (data not shown). The development of MCF7 aggregates into tumoroids 
exhibit a steady exponential growth, reaching a plateau of about 1 mm in diameter by day 
6 (Figure 12b, Figure 13a). The time-course of tumoroid formation depends on the 
composition of the tumoroids. The growth rate of MCF7 tumoroids is much greater than 
either MDAMB231 or coculture tumoroids (Figure 12c). 
 
Results also show that at day 1, the number of MDAMB231 aggregates is significantly 
higher than MCF7 monoculture and 1:1 concentration ratio coculture (Figure 13b). Only 
a fraction of these initial aggregates, however, develop to become larger tumoroids at 
later time points. A viable rim of cells approximately 100 µm is visible in the tumoroid 
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periphery. Necrotic cores in all tumoroids begin to appear once the aggregate diameter is 
greater than 300 µm (Figure 15). Saturation and stabilization of tumoroid size in E-cad 
positive MCF7 cell tumors may be partly due to depletion of nutrient content caused by 
diffusion limitations, in particular glucose and oxygen.  
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Figure 12 Size distribution for cell aggregates cultured in RWV. a) MDAMB231 cell 
aggregates seeded initially at 0.2 × 10
6
 cells per ml in 10 ml RPMI-1640 medium for 
days 1, 2, 4 and 6. b) MCF7 cell aggregates seeded initially at 0.2×10
6
 cells per ml in 10 
ml RPMI-1640 medium for days 1, 2, 4 and 6. c) 1:1 coculture cell aggregates seeded 
initially at 0.1 × 10
6
 cells per ml in 10 ml RPMI-1640 medium for days 1, 2, 4 and 6. 
 
3.3.3 Cellular Composition of Heterogeneous Tumoroids 
Tumoroids composed of these cell lines at 1:1 initial concentration ratio show that 24 
hours post seeding, aggregates are composed of both cell lines at equal concentrations 
(Figure 14). During the following days however, the concentration of MCF7 cells 
increases over MDAMB231 (Figure 14), suggesting that either a larger proportion of 
MCF7 cells underwent cell division compared to MDAMB231 cells or that MCF7 
singlets have a higher affinity to aggregate than MDAMB231 cells (Figure 13a). 
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Figure 13 a) Average diameter of the cell aggregates cultured in RWV follow an 
exponential growth pattern. Tumoroids display the typical solid tumor growth pattern of 
an exponential growth period followed by a plateau with little or no growth. b) Number 
of aggregates per unit area cultured in RWV and obtained from phase contrast images. 
The figure shows the mean of three different experiments (*p < 0.05). 
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Figure 14 Cellular composition of tumoroids. Initially, cells were seeded at 1:1 ratio at 
0.2 × 10
6
 cells per ml. MDAMB231 and MCF7 cell lines were relabeled red and green 
respectively prior to mixing. At each time point, aggregates were collected, and cells 
were counted using time-course fluorescent microscopy. The figure shows the mean of 
three different experiments (*p < 0.05).  
 
3.3.4 Cellular Spatial Distribution of Heterogeneous Tumoroids 
Coculture of breast cancer cell lines into tumoroids display morphological and 
developmental distinctions. Because MCF7 cells are E-cad and PR-positive and 
MDAMB231 cells are not, it is possible to gain information on the spatial distribution of 
these cell types in tumoroids using biomarkers in histology slides. Cell organization and 
thickness of the viable rim differs from tumoroid to tumoroid even at identical initial cell 
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type composition. However, most abundant cell types in tumoroids typically appeared 
preferentially at the outer layers of heterogeneous tumoroids (Figure 15a-i, b-i). 
Moreover, intensity of the proliferation marker ki67 staining decreases from the tumoroid 
surface toward the tumoroid core (Figure 15a-iv, b-iv) indicating that tumoroids grew 
fundamentally by surface growth. 
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Figure 15 Hematoxylin-eosin (HE) and immunohistochemical staining of progesterone 
receptor (PR), E-cadherin (E-cad) and proliferation marker ki67 are shown of day 8 
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stained 10 µm thick paraffin sections through spheroid cocoltures of three breast cancer 
cell lines formed in the RWV, and composed of different cell concentrations at initial 
density of 2×10
6
 cells per ml show a viable cell layer and necrotic core. Cell 
concentrations are a) 1 × 10
6
 cells per ml MCF7, 0.5 × 10
6
 cells per ml MDAMB231 and 
0.5 × 10
6
 cells per ml ZR751 and b) 0.5 × 10
6
 cells per ml MCF7, 1 × 10
6
 cells per ml 
MDAMB231 and 0.5 × 10
6
 cells per ml ZR751. Bar: 100 µm 
 
3.3.5 Cell Migration Potential of Heterogeneous Tumoroids 
MDAMB231 cells on the surface of heterogeneous tumoroids form protrusions on the 
periphery, resulting in the rougher surface in MDAMB231 rich heterogeneous tumoroids 
(Figure 15b-i, iii). This observation prompted us to investigate the morphology of 
tumoroid-extracellular matrix interactions. Heterogeneous tumoroids were placed onto 
collagen gels and cultured for 24 hours. Phase contrast and fluorescence microscopy 
images of tumoroids on collagen gel show frequent formation of footholds into the 
surrounding matrix (Figure 16a) by MDAMB231 cells on the surfaces of heterogeneous 
tumoroids whereas MCF7 cells do not appear to migrate into the surrounding matrix 
(Figure 16b). 
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Figure 16 Aggressiveness and metastatic potential of heterogeneous tumors highly 
depends on the cellular composition. Heterogeneous tumors composed primarily of 
MDAMB231 (red) show invasion of the surrounding collagen matrix, in contrast to 
tumors which are primarily composed of MCF7 (green). a) Phase contrast image of tumor 
spheroids composed of MDAMB231 and MCF7 cells; b) Fluorescent micrograph of the 
same field demonstrating the identity of the cells comprising the morphologically 
different tumor spheroids. Bar: 100 µm 
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3.4 Discussion 
Tissue engineering literature suggests that three-dimensional structures formed by 
cultured cells in vitro are better models of in vivo tissue than planar cultures of cell lines, 
particularly in mimicking some of the cell-cell, cell-matrix interactions found in vivo 
(Lelkes and Unsworth, 2002). Cancer research studies performed on monolayer culture 
conditions can not account for limitations caused by diffusion, cell-cell interactions and 
factors such as hypoxia, apoptosis and proliferation. In the present study, we used 
rotating wall vessel chambers for high throughput production of heterogeneous tumoroids 
using combinations of breast cell lines. We showed that a multitude of breast cell lines 
could be cocultured to form heterogeneous tumoroids of about 1 mm in diameter. 
Tumoroids reached their steady state size in approximately 6 days and were found to be 
viable even after 14 days of culture in RWV. MCF7 rich tumoroids developed faster into 
larger aggregates than MDAMB231 rich tumoroids. This finding is consistent with earlier 
in vitro studies of cells expressing E-cadherin that demonstrate an increased potential to 
aggregate (Byers et al., 1995). According to Ramsey et al., motile subpopulations in a 
tumor will spontaneously replace weaker intercellular adhesions with stronger ones until 
it approaches that configuration in which adhesion bonding is maximized (Ramsey et al., 
2005). When different cell populations are mixed as we did in this study, cells expressing 
similar adhesion molecules aggregate to each other with homophilic bonds (Yap, 1997).  
 
Tumoroids formed in this study exhibited morphological features observed in in vivo 
tumors of similar size such as the presence of a necrotic core and viable rim. Moreover, 
MDAMB231 cells on the surface of heterogeneous tumoroids often formed footholds of 
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linear extensions into the surrounding collagen rich matrix, mimicking breast cancer cell 
invasion into the stroma. Thus, the three-dimensional tumor model developed in this 
study allows for study of cell-cell interactions in tumor development.  
 
The coculture model presented here corresponds to early stages of tumor growth in the 
absence of vasculature (Kelm et al., 2003). As such, it provides a high throughput in vitro 
tumor model that could be potentially valuable for investigating early stages of tumor 
development. The ability to monitor the growth and spatial distribution of cancer cells in 
a high throughput in vitro system will aid our understanding of the early stages of cancer 
development. The model system developed here can be used to investigate the impact of 
cell phenotype heterogeneity on global gene expression profiles (microarray data) as well 
as developing in vitro drug testing and drug delivery systems. Comparing gene 
expression profiles of heterogeneous tumors against those of in vivo tumors is subject to 
future study. Effective therapeutic agents and trials for the treatment of malignant tumors 
should target the metastatic subpopulations of cells. Heterogeneous in vitro models could 
account for the mixed responses to detection, treatment and evaluation protocols as a 
result of tumor heterogeneity. Moreover, metastasis potential into different tissue types 
can be considered with this system by infusing heterogeneous tumoroids into 
microfluidic channels coated with cultured cells of other tissue types. 
 
 
 65 
CHAPTER 4: Protein Marker Profiling of Composite Breast Tumoroids: An 
Automated Image Analysis 
 
Summary 
This chapter presents an automated image analysis for protein marker profiling of 
composite breast tumoroids. It is a collaborative effort, with Dr. Bilge Karacali, taking 
the lead on the development of this novel image processing analysis for heterogeneous 
tumoroids. The manuscript containing this research is currently in review (Karacali et al., 
2007). Three-dimensional in vitro culture of cancer cells are used to predict the effects of 
prospective anti-cancer drugs in vivo. In this study, we present an automated image 
analysis protocol for detailed morphological protein marker profiling of tumoroid cross 
section images. Histologic cross sections of breast tumoroids developed in coculture 
suspensions of breast cancer cell lines, stained for E-cadherin and progesterone receptor, 
were digitized and pixels in these images were classified into five categories using k-
means clustering. Automated segmentation was used to identify image regions composed 
of cells expressing a given biomarker. Image analysis of adjacent histology slides stained, 
respectively, for Ecad and PR, accurately predicted regions of different cell phenotypes. 
Image analysis of tumoroid cross sections from different tumoroids obtained under the 
same coculture conditions indicated the variation of cellular composition from one 
tumoroid to another. Variations in the compositions of cross sections obtained from the 
same tumoroid were established by parallel analysis of Ecad and PR-stained cross section 
images. Proposed image analysis methods offer standardized high throughput profiling of 
molecular anatomy of tumoroids based on both membrane and nuclei markers that is 
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suitable to rapid large scale investigations of anti-cancer compounds for drug 
development. 
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4.1 Introduction 
Fast, repeatable, and reliable methods are needed for evaluating the efficacy of 
prospective drugs in cancer research. Cell lines derived from cancer tissues are used 
extensively to model in vivo drug response as they can be transferred, reproduced, and 
analyzed in standardized assay (Carmichael et al., 1998; Lacroix and Leclercq, 2004). 
Effects of therapeutic compounds have been studied widely on cell lines isolated from 
breast, skin, colon, prostate, lung, brain, and the bone marrow (Armstrong et al., 1992; 
Chang et al., 1987; Elder et al., 1997; Lim et al., 1999; Tolis et al., 1999; Janss et al., 
1998; Wang et al., 1998). A comprehensive database of several human cancer cell lines’ 
chemosensitivity to select anticancer drugs was presented (Dan et al., 2002). The 
limitations of two-dimensional assays of cancer cell cultures in representing in vivo tissue 
conditions may be due to the lack of cell to cell and cell to extracellular matrix interaction 
(Wiseman and Zerb, 2002).  
 
Three-dimensional cell cultures promote cell to cell interaction in a more realistic 
geometry (Bissell et al., 2002). Cancer cells grown in tumoroids interact with one another 
as well as with the extracellular matrix that they produce (Beaupain et al., 1999). While 
the tumoroids grown in vitro lack the actual tissue micro environment known to affect the 
tumorigenic properties of cell lines (Wiseman and Zerb, 2002; Bissell et al., 2002; 
Beaupain et al., 1999; Jessani et al., 2005), the high cost and low repeatability of in vivo 
tumor models in immune deficient host systems prevent standardized large scale and high 
throughput analyses. Therefore, in vitro tumoroids developed using cancer cell lines 
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remain the primary models for standardized high throughput studies of cancer (Mueller-
Klieser, 1997). 
 
The potential benefits of automated image cytology are widely recognized for rapid and 
standardized assessment of biomarker status (Walker et al., 2006) Comparisons of 
manual and automated methods in assessing biomarker expression showed a high 
correlation, establishing automated image analysis methods as effective and reliable 
alternatives to painstaking manual microscopic examinations (Lee et al., 2004; Tsiambas 
et al., 2006). Computational image analysis algorithms proposed in the literature for 
quantitative evaluation of histological tissue cross sections can be grouped under two 
categories based on the scale at which they characterize tissue anatomy (Christens-Barry 
et al., 1997; Demir et al., 2005).  
 
The first group focuses on the appearance of cell nuclei (Hoque et al., 2001; Dreyer et al., 
2003; Schmid et al., 2006; Roula et a., 2004; Raimondo et al., 2005), while the second 
group studies the appearance of cell clusters in terms of the spatial arrangement of cell 
nuclei as well as the texture characteristics of the tissue (Todman et al., 2001; Petushi et 
al., 2004; Braumann et al., 2005; Demir et al., 2005). The expressions of nuclei-bound 
biomarkers were analyzed by detecting the nuclei in digitized histological cross-section 
images, and then classifying the positively- and negatively-stained nuclei within the field 
of view (Mao et al., 2006; Kim et al., 2006; Spyridonons et al., 2002; Schnorrenberg et 
al., 2000). Lacking the well-defined spatial locus of the nucleus, membrane-bound 
biomarkers were assessed through densitometric analysis across larger tissue structures 
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(Charpin et al., 1998; 1999). A fractal-based texture analysis method was proposed to 
identify positively and negatively stained tissue distributions in histology slides (Gerger 
et al., 2004). A software platform capable of combining different computational modules 
for processing histology images has been developed to enable designing custom image 
analysis pipelines with separate detection layers for nuclei and cell membranes in high-
resolution histology images (Carpenter et al., 2005).  
 
Open access systems operated by internet web servers, such as EAMUS™ 
(http://eamus.de), have recently been developed for extracting quantitative parameters 
from immunohistochemically stained tissue slides (Kayser et al., 2006; Singh et al., 2005) 
and tissue microarrays (Chen et al., 2004). Several commercial software packages have 
also been developed for cytometric analysis of histological slides and tissue microarrays 
such as the Tissue Microarray Analysis Software (TMAx) by Beecher Instruments 
(Beecher Instruments, Inc., 686 Progress Way, Sun Prairie, WI 53590, USA), the 
Extended Slide Wizard by Tripath Imaging (Tripath Imaging, Inc., 780 Plantation Drive, 
Burlington, NC 27215, USA), the Discovery Image Analyser by Becton-Dickinson 
(Becton-Dickinson Biosciences, Postbus 757, 2400 AT Alphen aan den Rijn, The 
Netherlands), the TissueQuest software by TissueGnostics (TissueGnostics GmbH, 
Taborstraße 10/2/8, 1020 Vienna, Austria FN 234341 w) and the Automated Cellular 
Imaging System (ACIS) by Clarient (Clarient, Inc., 31 Columbia, Aliso Viejo, CA 92656, 
USA), along with the Stanford Tissue Microarray Analysis Software: CaseXplorer (Liu et 
al., 2002). Among these, ACIS in particular has been used extensively, in the analysis of 
immunohistochemically stained lung cancer specimens for p53, ki-67, and p120 status 
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(Hilbe et al., 2003) as well as HER-2/neu expression in breast cancer by both 
immunohistochemical staining and fluorescence in-situ hybridization (Ciampa et al., 
2006; Tawfik et al., 2006; Wang et al., 2001). However, a comprehensive methodology 
for automated analysis of histological sections of heterogeneous tumoroids stained for a 
variety of molecular markers, from construction of whole cross section images using 
overlapping snapshots to molecular profiling of DNA spots, has not been formalized. The 
differences in the microenvironment of the tumoroids to that of the actual tissue results in 
differences in the cross section images of tumoroids, and the computational algorithms 
used in studying histology slides obtained from surgically removed or biopsied 
specimens have not been validated on tumoroid cross section images. A typical example 
to these differences is a drastically increased number of overlapping nuclei due to much 
larger nuclear area (Volk et al., 1983). 
 
We have studied the anatomy of cocultures of poorly invasive and highly invasive breast 
cancer cell lines using digitized cross section images immunohistochemically stained for 
E-cadherin (Ecad) and progesterone receptor (PR) by automated image analysis methods. 
Positively and negatively stained regions of cross section images were delineated using 
image segmentation algorithms based on pixel color. The DNA spots were identified in 
positively and negatively stained image regions. Our results showed that the Ecad+/PR+ 
and Ecad-/PR- cell lines exhibited strong homophilic binding. This preference was more 
pronounced in invasive cells which produced several Ecad/PR deficient tumoroids. All 
image analysis algorithms were validated on synthetic images for segmentation accuracy 
and DNA spot profiling performance. These results indicated that the tumoroids 
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developed using mixture cell suspensions were anatomically heterogeneous, and the 
automated image analysis methods developed in this study enabled rapid and accurate 
morphological phenotyping of such tumoroids using immunohistochemical staining for 
both membrane and nuclear targets. 
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4.2 Materials and Methods 
 
4.2.1 Development of In-Vitro Tumoroids 
The tumoroids used in this study were described in a previous publication (Vamvakidou 
et al., 2007 I). Briefly, breast cancer cell lines of highly invasive (MDAMB231) and 
poorly invasive (MCF7, and ZR751) phenotypes were cocultured at respective 
concentrations of 25% and 75%, in a rotating wall vessel bioreactor to form a large 
number of heterogeneous tumoroids in a single cell culture experiment. Poorly invasive 
cell lines were estrogen receptor (ER), progesterone receptor (PR), and E-cadherin (Ecad) 
positive (Hall et al., 1990; Fabbro et al., 1986; Hiraguri et al., 1998; Engel et al., 1978), 
whereas the highly invasive MDAMB231 cells were ER, PR and Ecad negative (Pierceall 
et al., 1995). Histological sections of tumoroids were stained with hematoxylin and eosin, 
ER (mouse anti-ER antigen, clone 1D5, Zymed Laboratories Inc., 561 Eccles Avenue, 
South San Francisco, CA 94080, USA), PR (monoclonal mouse anti-human PR antigen, 
clone PgR 636, DAKO Corporation, 6392 Via Real, Carpinteria, CA 93013 USA), Ecad 
(mouse anti-Ecad antigen, clone 4A2C7, Zymed Laboratories Inc., 561 Eccles Avenue, 
South San Francisco, CA 94080, USA), and proliferation marker Ki-67 (monoclonal 
mouse anti-human Ki-67 antigen, clone MIB-1, DAKO Corporation, 6392 Via Real, 
Carpinteria, CA 93013 USA). In this paper, we have digitized and analyzed the tumoroid 
cross sections that were stained for Ecad and PR (shown in Figure 17). 
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Figure 17 Digitized Ecad (left) and PR (right) stained cross sections of a tumoroid.  
 
Visual inspection of the high magnification images of tumoroid cross sections obtained 
using coolscope indicated the presence of highly invasive (Ecad-/PR-) and poorly 
invasive (Ecad+/PR+) cell clusters on the same tumoroid cross section for a number of 
cross sections under consideration (Figure 18). 
 
Digitized images of histology sections of breast tumoroids obtained under coculture 
conditions were collected at x40 magnification scale using Coolscope VS Digital 
Microscope (Nikon, Kanagawa, Japan) and the dedicated Coolscope VS Suite (Bacus, IL) 
imaging software. Image collection involved consecutive overlapping snapshots at a 
color depth of 24 bits using the graphical user interface of the Coolscope VS Suite. These 
snapshots were later merged in software to produce a single image containing individual 
tumoroid cross sections. The pixel sizes of the resulting images were 0.17µm x 0.17µm 
(Figure 20).  
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Figure 18 Tumoroid cross-sections at 40× magnification at regions indicated on images 
shown in Figure 17. Both image blocks are of size 125µm × 125µm. Note the 
heterogeneity of tumoroid composition in terms of positively and negatively stained cells.  
 
Prior to processing, the color compositions of all image pixels were converted from the 
native RGB representation to the CIEL
*
a
*
b
*
 representation (CIE Colorimetry, 1986). The 
CIEL
*
a
*
b
*
 color space is characterized by the luminance L
*
 along with the chromaticity 
indices a
*
 and b
*
. One advantage of using the CIEL
*
a
*
b
*
 color representation instead of 
the RGB representation native to the image acquisition system is the linearization of the 
color differences: The CIEL
*
a
*
b
*
 color space is designed to capture the nonlinear 
perception of the human visual system, so that the Euclidean distances between colors in 
the CIEL
*
a
*
b
*
 space mimic closely the differences perceived by an average human eye 
(CIE Colorimetry, 1986). The CIEL
*
a
*
b
*
 space provides a device independent color 
representation by factoring in the white point of the image acquisition device. This 
enables standardized processing of images obtained using different imaging systems.  
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Ecad and PR staining patterns computed by our automated image analysis software and it 
indicates the connectivity of highly invasive (Ecad-/PR-) breast cancer cells in cell 
occupied regions of a tumoroid. Poorly invasive (Ecad+/PR+) breast cancer cells 
frequently tended to occupy the outer layers of the composite tumoroids, possibly due to 
their larger concentration (75%) in the coculture (Figure 19). 
 
 
Figure 19 Staining patterns obtained via computational image analysis in cross sections 
shown in Figure 17. Tumoroid heterogeneity is revealed by the intermixing of positively 
and negatively stained regions shown in red and blue respectively. Also note the strong 
agreement between the staining patterns of the Ecad stained (left) and the PR stained 
(right) cross sections. Positive staining is shown in red, while negative staining is shown 
in blue. 
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Figure 20 Image processing pipeline used to analyze immunohistochemically stained 
tumoroid cross section images. After the tumoroid cross sections were digitized at 40×, 
different tissue components were identified using unsupervised clustering and 
classification. Using the spatial distribution of pixels associated with positively and 
negatively stained cells, the staining patterns were identified. At the same time, the 
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spatial distributions of DNA-rich pixels were analyzed and individual DNA spots were 
identified. 
 
4.2.2 Segmentation of cell clusters based on membrane targeting biomarkers 
Pixel classes in Ecad-stained tumoroid cross section images were determined using k-
means unsupervised clustering on a reference image (Selim et al., 1984). The reference 
image was selected to exhibit all the regions of interest for studying the tumoroid cross-
section images in our dataset in abundance, and therefore, to present the most complete 
and statistically accurate description of the data for training the classifiers. The 
segmentations achieved on the reference image for k=2, 3, 4, 5, and 6 classes were 
evaluated visually for their ability to distinguish different tumoroid cross section image 
constituents.  
 
The segmentation obtained using k=5 delineated the following pixel classes presented in 
the order of light to dark: E1: bright pixels in regions void of tissues and cells; E2: pixels 
that belonged to cell cytoplasm; E3: pixels that belonged to chromatin rich regions such 
as the cross sections of cell nuclei; E4: pixels that belong to cell cytoplasm stained by 
diffusing Ecad staining on the cell membrane; and E5: the pixels that were on the 
membranes of the Ecad+ cells and their immediate vicinity. The cluster centers 
determined by the 5-class k-means clustering for the reference image were used in the 
segmentation by nearest neighbor classification of the images of Ecad-stained histology 
slides used in this study. Note that this algorithm was designed to identify pixel clusters 
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that exhibited statistically conspicuous color separation, and not to quantify the actual 
intensity of staining. 
 
Classification of pixels in images decorated by protein markers for Ecad into five 
categories was a first step in the automated delineation of the regions of the histology 
images composed of cells expressing the protein marker. In Ecad-stained cross section 
images, these regions typically contained pixels from four of the five categories described 
above (E2 to E5). Image regions that consisted of Ecad expressing cells were determined 
via automated classification of individual image pixels into belonging to either Ecad 
expressing or Ecad negative categories by thresholding of a weighted ratio of pixels that 
are in E4 and E5 classes in the immediate neighborhood of the pixel.  
 
4.2.3 Segmentation of cell clusters based on nuclei/cytoplasm targeting biomarkers 
Classification of the pixels in PR-stained tumoroid cross section images followed the 
same strategy as above. First pixel classes in a PR-stained reference image were 
determined via k-means clustering for k=2, 3, 4, 5, and 6. The segmentation with 5 
classes was determined visually to best capture the pixel types present in the cross section 
image. The pixels in PR decorated images were classified into the following categories: 
P1: pixels that belonged to tissue void regions; P2: pixels that fell on the cytoplasm of PR 
negative cells, P3: pixels that fell on the cytoplasm of PR positive cells; P4: pixels that 
corresponded to the chromatin containing regions in PR negative cells; and P5: pixels 
that belonged to chromatin-rich regions in PR positive cells. The cluster centers of these 
five classes were determined by the k-means unsupervised clustering. Then, the images of 
 79 
the PR-stained tumoroid cross sections used in the study were segmented by nearest 
neighbor classification using these cluster centers obtained for the reference dataset. 
 
The positively stained regions in PR-stained tumoroid cross section images were 
determined using a similar method as for Ecad-stained cross section images. An optimal 
threshold of 0.185 was determined by k-means unsupervised clustering with k=2 on the 
positive staining ratios from the reference PR-stained tumoroid cross section image after 
normalization (classes P3 and P5). This threshold was later used to identify the positively 
stained regions in all the remaining PR-stained cross section images.  
 
 
4.2.4 Accuracy of segmentation using adjacent histology slides decorated with 
membrane-targeting and nuclei-targeting biomarkers 
Segmentation accuracy on actual images was assessed using the staining patterns 
obtained for adjacent histology slides that were stained for Ecad and PR. Since the cells 
in the composite tumoroids were either Ecad+ and PR+ or Ecad- and PR-, the agreement 
between the staining patterns in Ecad-stained and PR-stained cross section images 
provided additional validation for the tissue segmentation algorithms.  
 
Two measures of aerial concentrations of cell phenotypes in a given tumoroid cross 
section image were used. The first measure was obtained by the percentage of positively 
and negatively stained regions across the whole cross section image. In addition, the 
detected DNA spots were classified as positively-stained or negatively stained based on 
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the whether their centers of mass were in positively or negatively stained regions. The 
percentage of positively and negatively stained DNA spots provided the second measure 
of cell phenotype concentration in tumoroid cross section images. These two measures of 
cell concentration were then compared and contrasted between Ecad-stained and PR-
stained cross section images.  
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4.3 Results 
 
Visual inspection of histology images of tumoroid sections decorated for Ecad or PR 
indicated that in many instances these cross sections cut across cells of highly invasive 
and poorly invasive phenotypes (Figures 21 and 22). The tumoroid shown in the figures 
is in the form of a cell-rich wall encompassing a largely cell free core. As the tumoroid 
grew with increasing durations of incubation, cell free core regions became apparent 
much more frequently, possibly as a result of insufficient diffusion of nutrients and 
oxygen across the thickness of the tumoroid. The tumoroid these images ranged in 
thickness from 100-140 µm. The presence of small cell clusters of different phenotypes 
on the same cross section side by side can be observed clearly in Figures 21 and 22, 
indicating that cells belonging to different phenotypes are able to adhere to each other 
even in the absence of E-cadherin (homotypic cell-cell adhesion molecules).  
 
Similarly, the visual inspection of the same figure shows that PR staining is also efficient 
in identifying the microscopic boundaries of cell clusters belonging to different 
phenotypes. The automated segmentation procedure described in the methods section 
separates image regions occupied by highly invasive cells (blue) from those regions 
occupied by poorly invasive cells at a coarser scale. The visual comparison of top and 
bottom rows of Figures 21 and 22 indicate that automated segmentation correctly 
captures the presence of different cell phenotypes in a histology slide image globally, 
without the need for visualization at the physical dimensions of a living cell. 
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Figure 21 Processing of membrane-targeting Ecad stained tumoroid cross section 
images. The original image at 40× (top), the segmentation (middle), and the deduced 
staining patterns are shown (left column) along with marked high magnification boxes of 
width 156µm (right column). 
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Figure 22 Processing of nuclei-targeting PR stained tumoroid cross section images. The 
original image at 40× (top), the segmentation (middle), and the deduced staining patterns 
are shown (left column) along with marked high magnification boxes of width 156µm 
(right column). 
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The automated image analysis showed that composite tumoroids that were developed 
using poorly invasive to highly invasive cells at a three-to-one ratio contained largely 
cells of poorly invasive phenotype (Figure 23). On the average, invasive cell phenotype 
occupied 34 % of the tumoroid cross section in images stained for Ecad and 39% of the 
cross section in images stained for PR. The composition of a tumoroid cross section 
varied from cross section to cross section for tumoroids developed under identical 
coculture conditions as shown in Figure 23. Adjacent cross sections of the same tumoroid 
stained for PR and stained for Ecad, however, showed closer prediction of the highly 
invasive cell phenotype regions. These results indicate the cell phenotype composition of 
a composite tumoroid cannot be estimated accurately by computing the corresponding 
composition in the images of a few tumoroid cross sections. On the other hand, 
automated segmentation developed in this study allows for the creation of tissue arrays 
from composite tumoroid cross sections for high throughput studies on potential drugs.  
 
 
Figure 23 Percentage of tumoroid areas occupied by positively and negatively stained 
regions. The positive staining percentages of PR and Ecad staining followed each other 
closely in general to within a difference of 12% even though differences as large as 30% 
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are also observed. A t-test analysis on the differences of positive staining percentages in 
Ecad and PR for zero mean returned a p value of 0.53 indicating that no systematic 
differences existed between the two. In the charts above, positive staining is shown in red 
and negative staining is shown in blue. 
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4.4 Discussion 
 
As modern pathology explores the use of automated image processing systems for 
accurate diagnosis of cancer class, similar automated techniques are needed to analyze 
images of tissue microarrays containing images from hundreds of different tissues in a 
single array. Tissue arrays that correspond to adjacent slides of a composite block are 
stained for different biomarkers (Camp et al., 2000; LeBaron et al., 2005; Rui et al., 
2005; Torhorst et al., 2001) and therefore it is necessary to identify the image regions that 
belong to cells expressing a particular biomarker.  
 
Since the image analysis methods presented in this paper operate on a pixel-based 
approach in identifying the staining of cell nucleus or membrane, they can be easily 
generalized to analyze sub-cellular staining characteristics of tumoroid cross-section 
images as well. Estimation of cell boundaries would be required to assess cytoplasmic 
staining on a per cell basis (Guillaud et al., 1997). In such instances, the image resolution 
stands the critical issue in recognizing positively stained pixels, since small pixel clusters 
may be lost through the course of mathematical morphological operations. Image 
resolution also underlines the distinction of the pixel-based strategy presented here from 
an object-based approach aimed at recognizing cellular structures in cross-section images 
first and then examining their staining properties (Kayser et al., 2006). Object recognition 
is inherently based on geometric detail, and requires resolution levels much finer than the 
typical size of the objects of interest. On the other hand, object-based strategies can 
achieve greater robustness to variations in tissue preparation and imaging conditions by 
invoking the geometric information in the process through model-based segmentation, 
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such as resolving instances of partial staining and overlapping nuclei (Guillaud et al., 
1997). 
 
The present image processing study involving in vitro tumoroid cross sections showed 
that these tumoroids capture the heterogeneous composition of human breast tumors. 
Moreover, our automated image analysis is capable of identifying image regions 
correspond to cells expression different biomarkers. The two biomarkers that we tested 
our image analysis rest in different regions of a breast cell: Ecad is located on cell 
boundaries whereas PR is a protein that is located in the nucleus as well as in the cell 
cytoplasm. Stains for these biomarkers often diffused around the biomarker in the 
tumoroid slides. Our image segmentation took stain diffusion into consideration via 
separate pixel classes representing cytoplasmic expression of respective biomarkers, and 
was able to identify regions of interest even in the presence of significant biomarker 
diffusion. Our study has also showed that detailed morphological computations can be 
carried with the automated image analysis on tumoroid cross sections as well as regular 
histology slides from surgically removed and biopsied specimens as was heavily studied 
in the literature that could potentially yield significant information on cell-cell 
interactions in cancer cell clusters.  
 
The need for automated image analysis and classification of tumoroid histology will 
increase with further incorporation quantum dots (Chan et al., 2002; Michalet et al., 
2005) and other nanosystems into tissue microarray technology for keeping track of 
multiple biomarkers on the images of the same histology slide. The accuracy at which 
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three-dimensional cell cultures emulate actual tumor tissue and in vivo tissue 
microenvironment can be improved further by co-culturing not only different cell lines 
but also cells of stromal origin. Coupled with the automated image analysis methods as 
presented here for rapid profiling of the molecular anatomy of the resulting tumoroids, 
this offers a great potential for standardized high throughput evaluation of prospective 
drugs for anti-cancer performance. 
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CHAPTER 5: Conclusions and Accomplishments 
 
In this work, we have conducted experimental and computational investigations to 
identify the critical molecular motifs that determine relapse in breast cancer and then 
explore these motifs through the use of an in-vitro tumoroid assay. First part of this thesis 
is concerned with statistical analysis of publicly accessible microarray data from different 
laboratories. The meta dataset used in this study was from general breast cancer 
population and was linked to clinical information so that relapse within five years 
duration was documented for each patient. Identification of breast cancer biomarkers for 
relapse is important for developing individualized therapies covering a range of 
interventions from tumor excision, standard chemotherapy to vaccine therapy. Proteins 
used in cell communication and signaling are potential biomarkers for a number disease 
states involving inflammation, and cancer. In order to identify potential biomarkers of 
relapse in breast cancer, we have analyzed relapse related microarray data from five 
different laboratories and additional data on breast cancer cell lines with poorly invasive 
and highly invasive cell phenotypes. We have identified a list of significantly altered 
genes for each dataset, and using a hypergeometric test, we computed the KEGG 
pathways that are significantly enriched in breast cancer relapse cases. KEGG pathways 
for MAPK signaling, focal adhesion and cytokine-mediated signaling have been enriched 
for relapse in breast cancer in four out of the five microarray databases. Similarly, these 
pathways appeared as enriched in comparisons of global gene expression profiles of 
poorly invasive and highly invasive cell lines. The set of genes along these pathways that 
were primarily upregulated in breast cancer relapse compared to non-relapse contained a 
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large number of genes that coded for extracellular proteins involved in signaling. A 
significant percentage of the extracellular genes in the list were also upregulated in 
relapse patients in a wide variety of solid tumor cancers. A set of genes coding for 
extracellular proteins are consistently upregulated in breast cancer patients with relapse in 
a multitude of microarray databases. A significant subset of these genes code for proteins 
found in the serum and as could be potential candidates for relapse biomarkers. 
 
The first part of this thesis presented strong supporting evidence on the relapse prediction 
potential of cultured cancer cells used in breast cancer research. We showed that 
MDAMB231 cell line and the MCF7 cell line captured the survival associated molecular 
profiles of breast tumor cells taken from metastatic and poorly invasive tumors, 
respectively. In the second part of this thesis, we used these two cell lines to form 
tumoroids in vitro as possible models for drug delivery into the tumor. As was discussed 
in the earlier sections of this thesis, breast tumors are typically heterogeneous and contain 
diverse subpopulations of tumor cells with differing phenotypic properties. Planar 
cultures of cancer cell lines are not viable models of investigation of cell-cell and cell-
matrix interactions during tumor development. In this thesis, we presented an in vitro 
coculture-based three-dimensional heterogeneous breast tumor model that can be used in 
drug resistance and drug delivery investigations. Breast cancer cell lines of different 
phenotypes (MDAMB231, MCF7 and ZR751) were cocultured in a rotating wall vessel 
(RWV) bioreactor to form a large number of heterogeneous tumoroids in a single cell 
culture experiment. Cells in the rotating vessels were labeled with CellTracker 
fluorescent probes to allow for time-course fluorescence microscopy to monitor cell 
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aggregation. Histological sections of tumoroids were stained with hematoxylin and eosin 
(H&E), progesterone receptor (PR), E- cadherin (E-cad) and proliferation marker, ki67. 
In vitro tumoroids developed in this study recapture important features of the temporal-
spatial organization of solid tumors, including the presence of necrotic areas at the center 
and higher levels of cell division at the tumor periphery. E-cad positive MCF7 cells form 
larger tumoroids than E-cad negative MDAMB231 cells. In heterogeneous tumors, the 
irregular surface roughness was mainly due to the presence of MDAMB231 cells whereas 
MCF7 cells formed smooth surfaces. Moreover, when heterogeneous tumoroids were 
placed onto collagen gels, highly invasive MDAMB231 cell rich surface regions 
produced extensions into the matrix whereas poorly invasive MCF7 cells did not. The 
fact that one can form a large number of 1 mm size tumoroids in one coculture, attest to 
the potential use of this system at high throughput investigations of cancer drug 
development and drug delivery into the tumor. 
 
The third part of the thesis is concerned with the development of image analysis for 
histological cross section of the breast culture cell tumoroids. The lead author in this third 
part is Dr. Bilge Karacali, who has designed and implemented the image analysis 
algorithm after having extensive discussions with me and we continued to collaborate 
through the completion of this chapter. Briefly, we developed an automated image 
analysis protocol for detailed morphological protein marker profiling of tumoroid cross 
section images. Histologic cross sections of breast tumoroids developed in coculture 
suspensions of breast cancer cell lines, stained for E-cadherin and progesterone receptor, 
were digitized and pixels in these images were classified into five categories using k-
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means clustering. Image analysis of adjacent histology slides stained, respectively, for 
Ecad and PR, accurately predicted regions of different cell phenotypes. Image analysis of 
tumoroid cross sections from different tumoroids obtained under the same coculture 
conditions indicated the variation of cellular composition from one tumoroid to another. 
Variations in the compositions of cross sections obtained from the same tumoroid were 
established by parallel analysis of Ecad and PR-stained cross section images. Proposed 
image analysis methods offer standardized high throughput profiling of molecular 
anatomy of tumoroids based on both membrane and nuclei markers that is suitable to 
rapid large scale investigations of anti-cancer compounds for drug development.
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